Document:

EX-10.11

 Exhibit 10.11 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 DEVELOPMENT AND SUPPLY AGREEMENT 

This Development and Supply Agreement (“Agreement”) is entered into as of June 24, 2009 (“Effective
Date”) by and between ViewRay Incorporated, a Delaware corporation (“ViewRay”), Manufacturing Sciences Corporation (hereinafter “MSC”) a Colorado corporation. 

Background 
 ViewRay possesses valuable
knowledge, expertise, intellectual properties and resources with regard to high performance radiation oncology devices. MSC possesses valuable knowledge, expertise, intellectual properties and resources with regard to the fabrication of Depleted
Uranium as utilized for radiation shielding. 
 ViewRay wishes to engage MSC to develop a Depleted Uranium radioactive source shield with Tungsten inserts
and a stainless steel outer wrapper (hereinafter “source shield”) which will meet certain agreed technical specifications for incorporation into ViewRay’s RenaissanceTM radiation therapy system. ViewRay also wishes to purchase
from MSC quantities of such radioactive source shields. 
 MSC is willing to provide ViewRay with development services for this device and is also willing
to sell ViewRay quantities of such device at favorable pricing in exchange for ViewRay’s agreement to maintain exclusivity of supply during a specified period. 

NOW THEREFORE, the parties agree as follows with respect to such development and supply arrangements. 

1. DEFINITIONS. 
 1.1 Defined Terms. Capitalized
terms used in this Agreement and not otherwise defined herein shall have the meaning set forth below. 
 “Affiliate”
means with respect to either party, any Person that, directly or indirectly, is controlled by, controls or is under common control with such party. For purposes of this definition only, “control” means, with respect to any
Person, the direct or indirect ownership of more than fifty percent (50%) of the voting or income interest in such Person or the possession otherwise, directly or indirectly, of the power to direct the management or policies of such Person.

 “Applicable Laws” means all applicable laws, statutes, regulations and ordinances. 

“Business Day” means any day other than a Saturday or Sunday that is not a national holiday in the United States. 

“Commercially Reasonable Efforts” means (i) with respect to any objective by any party, commercially reasonable,
diligent, good faith efforts to accomplish such objective as such party would normally use to accomplish a similar objective under similar circumstances; and (ii) with respect to any objective relating to the development or commercialization of
any product by any party, efforts and resources normally used by such party with respect to a product owned by such party at a similar stage in the development or life of such product. 

 “Confidential Information” means any proprietary or confidential
information of either party (including but not limited to all ViewRay Intellectual Property and all MSC Intellectual Property) disclosed to the other party pursuant to this Agreement, except any portion thereof which: (i) is known to the
receiving party, as evidenced by the receiving party’s prior written records, before receipt thereof under this Agreement; (ii) is disclosed to the receiving party by a third person who is under no obligation of confidentiality to the
disclosing party hereunder with respect to such information and who otherwise has a right to make such disclosure; (iii) is or becomes generally known in the public domain through no fault of the receiving party; or (iv) is independently
developed by the receiving party, as evidenced by the receiving party’s written records, without access to such information. 

“Control or Controlled” means, with respect to any Intellectual Property Right, the possession (whether by ownership,
license, or other agreement or arrangement existing now or after the Effective Date, other than pursuant to this Agreement) by a party or an Affiliate thereof of the right to grant to the other party a license as provided herein under such
Intellectual Property Right without violating the terms of any agreement or other arrangement of such party or its Affiliate with any third party. 

“FCA” means “Free Carrier (named place)”, as that expression is defined in Incoterms 2000, ICC Publishing
S.A. 
 “Intellectual Property Right(s)” means all rights in (1) U.S. and foreign utility and/or design
patents, patent applications, and utility models; (2) patents issuing on the patent applications described in clause (1); (3) continuations, continuations-in-part, divisions, reissues, reexaminations, or extensions of the patents or
applications described in clauses (1)-(2); (4) inventions, invention disclosures and improvements, whether or not patentable; (5) works of authorship, whether or not protectable by copyright,
all copyrights to such works, including all copyright registrations and applications and all renewals and extensions thereof; (6) rights in industrial designs, and (7) trade secrets, Confidential Information, know-how, processes,
algorithms, proprietary databases, and other proprietary information, and all tangible and intangible embodiments thereof. 

“MSC Intellectual Property” means, individually and collectively, all Intellectual Property Rights that are conceived,
discovered, developed, generated, created, made or reduced to practice or fixed in a tangible medium of expression by employees or consultants of MSC at any time prior to the Effective Date or after the Effective Date if such Intellectual Property
Rights are not based upon or related to the performance of the Program. The term MSC Intellectual Property, however, does not include any know-how, processes, information and data which is, as of the Effective Date or later becomes, generally
available to the public through no breach by ViewRay of its obligations under this Agreement. MSC Intellectual Property that exists as of the Effective Date includes the Intellectual Property Rights described in Attachment 3a.

 “Person” means any individual, corporation, association, partnership (general or limited), joint venture, trust,
estate, limited liability company, limited liability partnership, unincorporated organization, government (or any agency or political subdivision thereof) or other legal entity or organization, other than MSC or ViewRay. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 “Product” means a source shield that can be incorporated in the radiation
therapy subsystem of the ViewRay RenaissanceTM radiation therapy system. 
 “Program” means the development
program described in Attachment 1. 
 “Program Intellectual Property” means,
individually and collectively, all Intellectual Property Rights that are conceived, created, discovered, developed, generated, made or reduced to practice or fixed in a tangible medium of expression as part of or based upon or related to activities
undertaken as part of the Program whether: (a) solely by one or more employees or agents of MSC; (b) solely by one or more employees or agents of ViewRay; or (c) jointly by one or more employees or agents of MSC and one or more
employees or agents of ViewRay. Program Intellectual Property will be listed in Attachment 3c, which shall be amended from time-to-time to include new Program intellectual Property, in accordance with Section 5.3.
Attachment 3a will document existing MSC Intellectual Property which is of relevance to the Program, and Attachment 3b will document pre-existing ViewRay Intellectual Property relating to source
shield design. 
 “Specifications” means the specifications for the Product set forth in
Attachment 1, as they may be amended or supplemented by the parties pursuant to Section 2.4. 

“ViewRay Domain” means the [***]. 

“ViewRay Intellectual Property” means, individually and collectively, all Intellectual Property Rights that are
conceived, discovered, developed, generated, created, made or reduced to practice or fixed in a tangible medium of expression solely by employees or consultants of ViewRay at any time prior to the Effective Date or after the Effective Date if such
Intellectual Property Rights are not based upon or related to the performance of the Program. The term ViewRay Intellectual Property, however, does not include any know-how, processes, information and data which is, as of the Effective Date or later
becomes, generally available to the public through no breach by MSC of its obligations under this Agreement. ViewRay Intellectual Property that exists as of the Effective Date includes the Intellectual Property Rights described in
Attachment 3b. 
 1.2 Other Defined Terms. The following terms shall have the meanings set forth in the section appearing
opposite such term: 
  

			
	 “Acceptance”
	  	Section 2.3
	 “Act”
	  	Section 4.1
	 “affected party”
	  	Section 10.14
	 “Agreement”
	  	Recitals
	 “Applicable Standards”
	  	Section 4.1
	 “Bankruptcy Code”
	  	Section 5.1
	 “Change Control Document”
	  	Section 2.4

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
	 “Change Request”
	  	Section 2.4
	 “Deliverable(s)”
	  	Section 2.3
	 “disadvantaged party”
	  	Section 10.14
	 “DU”
	  	Section 2.3
	 “Effective Date”
	  	Recitals
	 “FDA”
	  	Section 4.1
	 “Force Majeure”
	  	Section 10.14
	 “Forecast”
	  	Section 3.2
	 “Full Production Period”
	  	Section 3.2
	 “Indemnifying Party”
	  	Section 8.4
	 “Losses”
	  	Section 8.2
	 “MDR”
	  	Section 4.3
	 “MSC”
	  	Recitals
	 “MSC Indemnified Party(ies)”
	  	Section 8.3
	 “Net Sales”
	  	Section 5.5
	 “NQA”
	  	Section 4.1
	 “NRC”
	  	Section 4.1
	 “ODH”
	  	Section 4.1
	 “Purchase Order”
	  	Section 3.3
	 “Regulatory Authority”
	  	Section 4.1
	 “Response Period”
	  	Section 2.4
	 “RMA”
	  	Section 3.9
	 “Rules”
	  	Section 10.2
	 “SOPs”
	  	Section 4.3
	 “Term”
	  	Section 9.1
	 “ViewRay”
	  	Recitals
	 “ViewRay Indemnified Party(ies)”
	  	Section 8.2.

 2. DEVELOPMENT PROGRAM 

2.1 Development of Product. The Program is directed toward the development of [***] of a Product that meets the applicable Specifications set forth in
Attachment 1 (including the documents referenced therein) and is expected to have a duration of [***]. 
 2.2 Progress
Reports. (a) ViewRay and MSC shall periodically meet, in person or by telephone or videoconference at such times and places as are mutually agreed upon, for MSC to provide ViewRay with an update on the status of the progress of the Program.
ViewRay and MSC shall each be responsible for its own expenses incurred in connection with attending such meetings. The parties’ representatives for purposes of meetings under this Section 2.2 will be MSC’s Director of Engineering, or
closest equivalent existing at the time, and ViewRay’s Manager of Hardware Development, or closest equivalent existing at the time. 

(b) MSC shall provide ViewRay in advance of each meeting pursuant to Section 2.2(a) an agenda for such meeting and reasonably-detailed
written reports describing the results of the Program, including difficulties encountered in achieving the technical objectives of the Program 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 
during the period since their last meeting. It is understood and agreed that neither party may change the Specifications without the consent of the other party using the procedure set forth in
Section 2.4. 
 2.3 Deliverables. (a) MSC will produce the deliverables due under Attachment 1 (each, a
“Deliverable”) on the schedule set forth in Attachment 1. ViewRay and MSC shall jointly work to test each Deliverable against the Specifications as shown in Attachment 1.
ViewRay shall be responsible for [***]. Said testing may include [***] in the Depleted Uranium (“DU”) portions of the Deliverable which could adversely impact its shielding effectiveness; and may require shipment of the
Deliverable(s) to a third party facility or to ViewRay’s Oakwood Village facility. If shipment to a third party facility or ViewRay’s facility is made, then ViewRay will work with MSC to arrange for shipment of the Deliverable(s) and
ViewRay will pay for all shipping related costs. If ViewRay accepts the Deliverable based on such testing, ViewRay shall acknowledge its acceptance (“Acceptance”) of the Deliverable in writing. If ViewRay rejects the Deliverable,
ViewRay shall provide MSC with notice of rejection, including a reasonably specific description of the deficiencies alleged. MSC will use Commercially Reasonable Efforts to cure any such deficiencies in an expedient manner and either “re-deliver” such Deliverable to ViewRay within ten (10) Business Days following the notice of rejection or, if MSC cannot accomplish such re-delivery within
such 10-Business Day period deliver to ViewRay within such 10-Business Day period a plan for curing said deficiencies. If MSC makes
re-delivery of the Deliverable, ViewRay shall, following its receipt of the re-delivered Deliverable, accept or reject the Deliverable using the procedure specified
above. If MSC instead provides a correction plan for such Deliverable, ViewRay shall within five (5) Business Days following receipt of such correction plan either agree to, offer modifications of or reject said correction plan. The parties
shall repeat the above process until the earlier of the date that a mutually acceptable correction plan is agreed or thirty (30) Business Days following ViewRay’s notice of rejection. If the parties are unable to agree on a mutually
acceptable correction plan, and do not extend the timeframe for reaching an accepting a mutually acceptable plan, then ViewRay may terminate this Agreement and ViewRay will “return” the Deliverable to MSC and MSC shall, within thirty
(30) days following receipt of the rejected Deliverable, return to ViewRay all sums (if any) paid by ViewRay to MSC for the Deliverable that is the subject of such rejection (but shall not be required to return the funding provided pursuant to
Paragraph 1 of Attachment 2 through the date of termination). If the parties do agree upon a correction plan, then MSC shall perform such correction plan and
“re-deliver” the Deliverable within the agreed time period. ViewRay shall, following its receipt of the re-delivered Deliverable, accept or reject the
Deliverable using the procedure specified above. The process specified in this Section 2.3 shall be repeated until the earliest of the date: (i) ViewRay accepts the re-delivered Deliverable; or
(ii) ViewRay rejects the Deliverable [***] for failure to comply with the Specifications; or (iii) [***] elapses from the initial notice of rejection. If the parties are unable to resolve such nonconformity within such time period, then
ViewRay may terminate this Agreement and ViewRay may “return” the Deliverable to MSC and MSC shall, within thirty (30) days following receipt of the rejected Deliverable, return to ViewRay all sums (if any) paid by ViewRay to MSC for
the Deliverable that is the subject of such rejection (but shall not be required to return the funding provided pursuant to Paragraph 1 of Attachment 2 through the date of termination. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b) It is understood and agreed that the Deliverables [***] for ViewRay to make payment of the
progress payments (if any) specified in Attachment 2, but if any Deliverable delivery or redelivery [***] in accordance with the [***], ViewRay [***] such Deliverable delivery or redelivery. Notwithstanding the foregoing,
Acceptance will not relieve MSC of its obligation to [***]. ViewRay’s obligations to pay for the Deliverables are subject to Acceptance, ViewRay shall have no obligation to pay for Deliverables except to the extent they are the subject of
ViewRay’s Acceptance. 
 (c) ViewRay will use Commercially Reasonable Efforts to test each Deliverable as quickly as practicable and in
any event within thirty (30) days of “delivery” of such Deliverable. In the event that ViewRay has not tested a Deliverable within sixty (60) days, then [***]. 

2.4 Changes. (a) During the Program, ViewRay may request amendments to Attachment 1 to effect changes in the
Specifications. If ViewRay wishes to make a change it shall notify MSC of the requested change specifying the change with sufficient details to enable MSC to evaluate it (a “Change Request”). Within ten (10) Business
Days, or such longer period as may be agreed to between the parties, following the date of MSC’s receipt of a ViewRay Change Request, MSC shall deliver a document that: (i) assesses the impact of the change on the schedule, and
(ii) incorporates a description of the requested change and the price therefor (a “Change Control Document”). 

(b) Within ten (10) Business Days following ViewRay’s receipt of a MSC Change Control Document (“Response
Period”), ViewRay will notify MSC whether or not it accepts the Change Control Document. If ViewRay accepts the Change Control Document, then the provisions of this Agreement shall be deemed amended to incorporate such change in
accordance with the Change Control Document. If ViewRay notifies MSC not to proceed within the Response Period, then the Change Request shall be deemed withdrawn and MSC shall take no further action in respect of it. If MSC has not received any
notice by the expiration of the Response Period, then ViewRay shall be deemed to have advised MSC not to proceed. A separate Change Control Document will be required for each Change Request but a Change request may include multiple changes; and each
Change Control Document will become subject to this Agreement when signed by MSC and ViewRay. 
 (c) MSC may not make any changes in the
form, fit, function, design, manufacturing process, manufacturing location or appearance of the Products or the Specifications without ViewRay’s prior written approval, which shall not be unreasonably withheld. 

(d) It is the intent of the parties that the Specifications have been defined broadly enough and with sufficient detail to accomplish
ViewRay’s goal for the Product without price increases even if the services are changed pursuant to this Section 2.4; provided that such changes, as documented in a Change Control Document, do not change the scope of the tasks
contemplated by the Specifications, as reasonably determined by MSC. 
 2.5 Success Criteria. If the Product prototypes delivered at the completion
of the Program meets the applicable Specifications, then the provisions of Section 3 shall take effect. If the Product prototype delivered at the completion of the Program does not meet the Specifications or 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
if ViewRay and MSC determine during the course of the Program that the results of the Program are unsatisfactory; which determination shall be made with reference to the prospects for realizing
Products that meet the Specifications then in each case they may mutually agree to terminate the Program under Section 9.2(b). If the parties do not agree with respect to termination of the Program, they shall resolve such dispute using the
procedure specified in Section 10.2(a)-(b). ViewRay’s notice of Acceptance of the final Deliverables shall confirm the end of the Program and the initiation of the commercial supply arrangements
described in Section 3. 
 2.6 Pricing. Pricing for effort and items delivered under this Section 2 will be as set forth in
Attachment 2. 
 2.7 Payment. All payments under this Section 2 will be made by check or wire transfer. Payments will
be made in US dollars. All amounts due under this Section 2 will be due within thirty (30) days of Acceptance (to the extent applicable as indicated on Attachment 2) and following receipt of invoice. MSC will invoice
ViewRay upon completion of each Program Phase Milestone as per Attachment 2. 
 3. PURCHASE OF PRODUCTS AND TERMS OF SALE

 3.1 Supply. If the Products meet the Specifications then ViewRay will purchase from MSC during the period ending on the fifth anniversary of
the Effective Date ViewRay’s requirements for the Products. 
 3.2 Purchase Forecasts. At least one hundred [***] prior to the first delivery to
ViewRay of commercial Products, ViewRay will deliver to MSC a [***] rolling forecast (the “Forecast”). The Forecast will cover the [***] commencing with and including the calendar month in which the first delivery of Products
is to occur. After delivery of the initial Forecast, the Forecast will be updated on a [***] basis. During the period prior to the date when ViewRay Product demand (as measured by units of Product received by ViewRay), averages [***] or more
Products per month over a [***] period the Forecast shall be non-binding until [***] prior to the forecast shipment date at which time the quantities become binding on ViewRay. Thereafter (the “Full Production Period”), the
Forecast shall be non-binding until [***] prior to the forecast shipment date at which time the quantities become binding on ViewRay. 
 3.3 Product
Orders. ViewRay will submit to MSC firm written purchase orders (each a “Purchase Order”) for the purchase of Products at least sixty (60) days prior to the specified delivery date of the ordered Products.
Each Purchase Order will specify the quantity or, if more than one shipment is requested, quantities of Products ordered, the requested delivery date or dates, and ship-to locations. Orders will be placed by
ViewRay to MSC by mail or facsimile, or by other means agreed upon by the parties. In the case of conflict between the provisions of this Agreement and either the standard printed terms of any Purchase Order or the standard printed terms of sale of
MSC, the provisions of this Agreement will control. Purchase Orders [***], but ViewRay may [***]. 
 3.4 Acceptance; Obligation to Supply.
(a) MSC will acknowledge all Purchase Orders within five (5) Business Days following receipt of same and will deliver all orders within ninety 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 
(90) days following the date such Purchase Order is received. MSC will accept all Purchase Orders for a particular calendar month to the extent that the Purchase Order (i) does not
exceed the amount of the firm Forecast for such calendar month, and (ii) requires delivery no less than sixty (60) days following the date on which MSC receives the Purchase Order. MSC will not be in breach of this Section 3.4 if
MSC’s failure to supply Products is due to a Force Majeure event or if MSC’s failure is limited to quantities in excess of the quantities specified in the binding Forecast period. 

(b) Each party will promptly notify the other party of any circumstances that it believes may be of importance as to MSC’s ability to
meet ViewRay’s needs for the Products in a timely manner. If the Forecasts indicate that ViewRay’s need for the Products will exceed MSC’s existing capacity to supply the Products, the parties will determine in good faith whether MSC
successfully can expand its production capacity so as to meet ViewRay’s needs in a timely manner. 
 3.5 Pricing. (a) After furnishing
[***] under the Program covered by Section 2, the next [***] of Products purchased, pursuant this Section 3 (i.e., units [***]), will be priced at $[***] per unit. 

(b) The prices for subsequent units of Product, from unit [***] up to and including unit [***], purchased by ViewRay pursuant to
this Section 3 shall be priced at $[***] per unit. Prices stated are firm for such [***] units of Product ordered and for which delivery is requested within [***] after the Effective Date. The pricing for any portion of such
[***] units of Product ordered after the expiration of such [***] period or with delivery requested after such [***] period, the price per unit of Product will increase by [***]. 

(c) Pricing and the pricing scheme, including quantity discounts, for additional units of Product purchased by ViewRay beyond the initial
[***] units will be established using the procedure set forth in this Section 3.5(c). Not later than the date MSC delivers the [***] unit of Product to ViewRay pursuant to this Section 3, at MSC’s option, MSC may calculate
and compare its actual direct costs of production for Products (i.e., for the [***] units of Products delivered pursuant to this Section 3), against its forecasted direct costs of production of Products, which formed the basis of the
pricing applicable for Product units [***] in Section 3.5(b) and request a pricing adjustment pursuant to this Section 3.5(c). If MSC determines that it will perform the estimated versus actual direct cost of production comparison,
then MSC will provide, ViewRay with a copy of such comparison, including documentation of such price components, and may request a one-time price adjustment that will be applicable for units of Product after unit [***] to cover any variance
between the estimated direct costs of production and the actual direct costs of production. ViewRay will have thirty (30) days to review the proposed price adjustment and will either accept it or reject it; it being understood that in the event
ViewRay rejects the proposed pricing adjustment, and the parties are unable to negotiate pricing that is mutually acceptable within sixty (60) days following such rejection, [***] shall be of no further effect. If MSC does not exercise its
option pursuant to this Section 3.5(c) it shall notify ViewRay at the time it delivers the [***] unit of Product and the pricing for additional units of Product supplied to ViewRay pursuant to this Section 3 shall be $[***] per unit,
subject to the adjustments set forth in Sections 3.5(d)-(e). 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 For purposes of this Section 3.5(c), MSC’s “direct costs of production” means
the [***] (including [***]) and [***] (including [***]) specifically allocable to the [***] of the [***]; such calculation and allocation being based upon generally accepted accounting principles and contract manufacturing industry standards and
consistent with the normal accounting practices for all products manufactured in the applicable facility. Any significant costs not described above or unusual cost items (i.e. [***]) shall be provided to ViewRay and subject to approval prior to
inclusion in the direct costs of production. 
 (d) Not more than [***] of the date that MSC delivers the [***] unit of product per
Section 3.5(c), MSC will adjust the prices for the Products, units [***] and beyond, during the next [***] period to reflect increases or decreases in the cost of [***] for the production of Products, provided that the adjustment for [***]
shall not exceed the change, if any, in the [***] as compared to the [***]. Any such price adjustment shall be made with notice to ViewRay, including documentation of such [***] price changes and upon ViewRay’s request, MSC shall make all
applicable books and records available for such inspection during normal business hours at MSC’s facility for purposes of verifying such cost adjustments. [***], as published by the [***]. In the event that the [***] precludes its further use
under this Agreement, ViewRay and MSC shall substitute another comparable measure published by an agreed-upon source. 
 (e) Except as
otherwise agreed by the parties or as provided in Sections 3.5(b), 3.5(d) and 3.11(a), MSC will not increase prices for the Products. 
 3.6
Payment. All payments under this Section 3 will be made by check or wire transfer. Payments will be made in US dollars. All amounts due under this Section 3 will be due within thirty (30) days of receipt of invoice. MSC will
invoice ViewRay upon shipment. 
 3.7 Resale Prices. Nothing contained herein shall be deemed to limit in any way the right of ViewRay to determine
the prices at which, or the terms on which, the Products purchased by ViewRay may be resold by ViewRay as part of ViewRay products or services. 
 3.8
Shipping. MSC shall arrange for shipment and invoicing to ViewRay of the Products ordered by ViewRay via common carrier, FCA MSC’s facility. ViewRay shall pay all transportation, customs, duties and other governmental charges, if any,
relating to the importation and sale of the Products, and shall have all responsibility for storing and clearing the Products through all customs and importation requirements. 

3.9 Defective Product. (a) MSC will at its expense and at no further cost to ViewRay replace Products that do not conform to the applicable
warranties specified in Section 7.2 during the applicable warranty period specified therein using the procedure specified in this Section 3.9. ViewRay will notify MSC in writing of any alleged defect of Product, will request a Return
Material Authorization (“RMA”) number and will within 30 days of receipt of such RMA number return such Product to MSC freight prepaid and properly insured, along with a reasonably detailed statement of the claimed
defect and proof of date of purchase. Such notice and statement may be sent to an e-mail address provided by MSC, which will initially be [***]. MSC will use Commercially Reasonable Efforts to deliver
replacement Product to ViewRay or its designated customer freight prepaid and properly insured with earliest delivery which can be 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 
obtained subject to sub MSC and/or MSC availability of said parts; provided, that for those Product components that are the subject of Section 3.9(b), ViewRay may elect to use the
procedure described in Section 3.9(b) to replace the applicable Product components. In the event that MSC reasonably determines that any allegedly nonconforming Product is in fact not defective (including Product that has been modified,
misused, abused or the subject of unauthorized repair), MSC will notify ViewRay in writing and ViewRay will [***] related to the [***], the [***], and the [***] (if applicable). ViewRay will only return Products to MSC with MSC’s prior written
approval. If ViewRay disputes MSC’s determination that a Product is not defective, the dispute will be discussed and resolved using the procedure provided in Section 10.2. 

3.10 Manufacturing Rights. (a) if MSC fails to supply Product ordered by ViewRay in accordance with the terms of this Agreement regarding the
quantity or quality of Products supplied to ViewRay, then MSC shall within ten (10) Business Days of said failure present ViewRay with a plan to remedy the problem and shall use Commercially Reasonable Efforts to execute such plan and remedy
the problem or MSC shall secure an alternative source of supply within a reasonable time at no cost to ViewRay. Any such alternative source of supply shall be on terms substantially identical with the terms of this Agreement. If MSC is unable to
provide a plan to remedy the problem or secure an alternative source of supply within [***] after its initial failure to supply, then MSC shall consult with ViewRay and the parties shall work together to remedy the problem. If MSC is unable to
remedy the supply problem after an [***] (or longer as agreed in writing by the parties), commencing with the date upon which such failure to supply began, then ViewRay may at its option, and upon notice to MSC, manufacture the Products itself or
through a third party in accordance with the provisions of Section 3.10(b). 
 (b) If ViewRay notifies MSC that ViewRay will
manufacture the Products itself or through a third party, MSC shall (1) deliver to ViewRay within thirty (30) days media embodying or disclosing all Program technology and Program proprietary or intellectual property rights necessary to
enable ViewRay or its designee to manufacture Products conforming with the Specifications; and (2) provide ViewRay or its designee, upon request, with reasonable assistance in establishing a back-up
manufacturing line. ViewRay shall require any third party ViewRay designates to manufacture Products pursuant to this Section 3.10, to agree in writing to observe the terms of this Agreement relating to confidentiality and the manufacture of
Products. Notwithstanding any provision of this Section 3.10 to the contrary, in no case shall MSC be required to pay ViewRay in respect of any Products purchased by ViewRay from a third party operating a
back-up manufacturing line established pursuant to this Section 3.10 or manufactured by ViewRay or its Affiliates pursuant to this Section 3.10. 

(c) Within three (3) months following the date ViewRay accepts the final Deliverable pursuant to Section 2, MSC shall provide
ViewRay, upon request, with assistance in qualifying a second source for the Products in the event that ViewRay should need to resort to this Section 3.10 upon a MSC supply failure. MSC shall deliver to ViewRay or the proposed second source
manufacturers media embodying or disclosing all information necessary to enable ViewRay and such second source manufacturer to evaluate their ability to manufacture Products conforming with the Specifications; and MSC shall make itself available to
respond to 
  
 [***] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
reasonable requests for information concerning the manufacturing requirements for the Products. All such disclosure to ViewRay shall be subject to Section 6 and all such disclosures to
second source manufacturers shall be made to such second source manufacturers under a written confidentiality containing terms no less restrictive than Section 6. ViewRay shall [***] in providing such assistance. 

3.11 Changes. (a) The Product Specifications for “commercial” Product supplied pursuant to this Section 3 may be modified or
changed only by ViewRay. ViewRay shall use the procedure specified in Section 2.4(a)-(b) to request such modifications or changes, except as modified in this Section 3.11. To the extent that any such
modification or change results in an increase or decrease in the cost of manufacturing any Product or requires additional capital investment or other material changes to the manufacturing process, the parties shall jointly examine and mutually agree
upon the consequences thereof and shall make an appropriate increase or decrease to the purchase price of such Product arising from such modification or change. In the event that any such change or modification results in the obsolescence of any raw
materials, work-in-process, and/or finished materials, the cost of any such obsolescence shall be the sole responsibility of ViewRay to a maximum of [***] of the change date. At least [***] prior notice is required for any requested Product
Specifications change pursuant to this Section 3.11; provided, however, that if any requested Product Specifications change requires additional regulatory approval(s), the implementation of such requested change shall in no event
be required until [***] after such approval(s) have been obtained. MSC shall not be required to implement any change to the Product Specifications that it reasonably believes will prevent it from being able to perform in accordance with the terms of
this Agreement unless such terms are modified. If MSC notifies ViewRay that it believes the preceding sentence is applicable the parties shall meet and attempt to resolve the matter within ninety (90) days using the procedure specified in
Section 10.2 if necessary; during any such period the Product will continue to be manufactured under the Product Specifications without such modification. If the parties are unable to resolve such matter within such 90-day period, then ViewRay may terminate this Agreement in accordance with Section 9.2(b) and MSC shall continue to supply the Product to ViewRay under the Product Specifications without such modification for
a period of up to [***] using the procedure specified in Section 9.3(c). 
 (b) MSC will not alter, modify, add to, or otherwise change
the Product Specifications, Product, or any materials, suppliers or manufacturing techniques used in the design or production of the Products that will or may possibly affect the form, fit or function of the Products without ViewRay’s prior
written approval. ViewRay may require MSC to make changes in raw materials or processes subject to a mutually agreed price adjustments. MSC may rebalance its production line in its reasonable business judgment; provided that the rebalancing
makes no change to and has no effect on the form, fit or function of the Products. ViewRay will not make any changes to the Product Specifications without notifying MSC in accordance with section 3.11(a). 

4. QUALITY ASSURANCE; SUPPORT 
 4.1 Manufacturing
Practices; Testing. MSC shall manufacture the Products supplied pursuant to Section 3 in accordance with mutually agreed quality standards and the Specifications. MSC 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
will install and maintain effective quality control systems, conduct quality assurance testing and keep comprehensive statistical process control records conforming to (1) standards provided
or approved by ViewRay and/or required of such process or processes for similar products; (2) appropriate best practices, including the then applicable good manufacturing practices regulations of the U.S. Food and Drug Administration
(“FDA”) under 21 C.F.R. Part 820, and the then applicable Nuclear Quality Assurance (“NQA”) regulations of the Nuclear Regulatory Commission (“NRC”) under
10 C.F.R. Part 830 or corresponding “Agreement State” regulations (as defined under the NRC regulations), or comparable regulations of any other supra-national, regional, federal, state, or local regulatory agency or
authority that has authority to grant registrations, authorizations, licenses and approvals necessary for the commercial manufacture, distribution, marketing, promotion, sale, use, importation, or exportation of the Products (each, including the
FDA, the NRC and the Ohio Department of Health (“ODH”) (as an Agreement State), a “Regulatory Authority”) that apply to the manufacture of the Products and the delivery of the Products to ViewRay
(“Applicable Standards”); and (3) other requirements set forth herein. 
 4.2 Regulatory Clearances. ViewRay will have
sole responsibility and authority for obtaining and maintaining regulatory clearances of the ViewRay system, including the Product (and all improvements or variations to the Product developed during the term of this Agreement), including without
limitation obtaining and maintaining approvals and clearances from the FDA, the ODH and any other Regulatory Authority necessary for the handling of DU in connection with the ViewRay system incorporating the Product or the commercial distribution
and sale of the ViewRay system incorporating the Product. All regulatory filings with the FDA, ODH or any other Regulatory Authority relating to the ViewRay system incorporating the Product will be made in the name of ViewRay or its designee and
ViewRay will be responsible for maintaining the required records for such system. 
 4.3 Quality Assurance Inspections. (a) During regular
business hours and upon reasonable advance notice and in a manner that does not disrupt or interfere with the business of MSC, MSC will permit ViewRay and its agents and its customers to inspect the facilities of MSC and provide access to MSC’s
manufacturing quality control documentation related to the Products to the extent necessary for, and for the purpose of assessing MSC’s compliance with this Agreement. As a condition of provision to ViewRay agents or ViewRay customers of access
to MSC’s facilities and documentation, all information obtained by ViewRay agents or ViewRay customers as a result of such access will be MSC Confidential Information for purposes of this Agreement. MSC may require any agent or customer of
ViewRay seeking access to MSC’s facilities under this Section 4.3(a), as a condition to such access, to execute a standard confidentiality agreement with MSC under which such agent agrees to treat information disclosed during such
inspection as the Confidential Information of MSC under terms and conditions no less restrictive than the terms contained in Section 6.2. 

(b) If an inspection pursuant to Section 4.3(a) reveals that the facilities used to manufacture Products do not satisfy the Applicable
Standards in all material respects, then ViewRay will promptly provide to MSC written notice of such fact, which notice will contain in reasonable detail the deficiencies found in the manufacturing facilities and, if practicable, those steps ViewRay
believes MSC should undertake in order to remedy such deficiencies. MSC will remedy such deficiencies within a reasonable period of time after receipt of such written notice. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c) MSC will maintain manufacturing quality documentation and will certify that Product was
manufactured and tested in accordance with the applicable Specifications and Applicable Standards. ViewRay may request copies of such certifications as part of the inspections permitted under Section 4.3(a). 

(d) MSC will comply with the applicable Specifications and Applicable Standards in its manufacturing of the Products. Prior to shipping any
Product, MSC will carry out the Product tests specified in the applicable Specifications on each Product. If a Product or any part of a Product fails to meet the Specifications, the Product will be repaired or replaced by MSC as set forth in
Section 7.4.3 and the relevant test will be repeated until such Product passes such test requirements. No Product will be shipped to ViewRay or its designee without passing all tests specified in the Specifications. 

4.4 Recalls. (a) Prior to the commercial release of the ViewRay system incorporating the Product, ViewRay will provide MSC with ViewRay’s
standard operating procedures (“SOPs”) as to recalls. If either party becomes aware of information about any Product indicating that it may not conform to the applicable Specifications, it will promptly so notify the other
party. The parties will promptly confer to discuss such circumstances and to consider appropriate courses of action, which courses of action will be consistent with the SOPs. ViewRay will have the right to initiate, and will bear all costs
associated with, a recall, withdrawal, or field correction of the Product for any reason; provided that ViewRay may proceed against MSC pursuant to Section 7.3 if such recall, withdrawal, or field correction of the Product is the direct
result of (i) any breach by MSC of its duties under the Agreement or (ii) MSC’s negligence or willful misconduct. 
 (b) With
respect to any recall, withdrawal, or field correction of a Product, ViewRay or its designee will be responsible for coordinating all of the necessary activities in connection with such recall, withdrawal, or field correction. ViewRay and MSC will
coordinate any statements to customers and the media, including, but not limited to, press releases and interviews for publication or broadcast and neither party will issue any such statements without consulting with the other. The parties will
reasonably cooperate with each other in the conduct of such activities and will perform any acts reasonably requested by the other party to facilitate the recall, withdrawal or field correction. Each party will keep the other party fully informed of
progress and in relation to all material decisions or actions such party undertakes pursuant to this Section 4.3(b). 
 (c) Each party
will promptly (within 2 working days unless a shorter time period is required under applicable law) notify the other party in writing of any event or complaint that gives rise or could give rise to the need to file a Medical Device Report (an
“MDR”) within the meaning of the Federal Food, Drug and Cosmetic Act of 1941, as amended (the “Act”) or a Notification of Noncompliance, Defect or Incident Report, within the meaning of 10 C.F.R.
Part 21 or a similar report under the laws or regulations administered by any Regulatory Authority, with respect to any Product or the manufacture, distribution or use thereof. Each such written notice will be 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Confidential Information under this Agreement. If, as a result of any corrective action or any final, non-appealable or non-appealed governmental or court action, a report, notification,
withdrawal, recall, or field action is required to be issued for any Product sold hereunder, ViewRay will bear the costs and expenses of and will be responsible for all such reports, notifications, withdrawals, recalls, or field actions but may
proceed against MSC pursuant to Section 7.3 if such report, notification, withdrawal, recall, or field action is the direct result of (i) any breach by MSC of its duties under the Agreement or (ii) MSC’s negligence or willful
misconduct. 
 5. LICENSES; PROPRIETARY RIGHTS 
 5.1
MSC Licenses. (a) MSC hereby grants to ViewRay and ViewRay hereby accepts, a worldwide, perpetual, paid-up and royalty-free license, including the right to grant sublicenses, to use the MSC
Intellectual Property Rights and the Program Intellectual Property Rights owned by MSC for the purpose of developing Products and delivering services that embody or utilize the Products to customers within the ViewRay Domain. ViewRay will not use
MSC Intellectual Property for any other purpose, without MSC’s prior written permission and ViewRay shall not grant, or attempt to grant, a sublicense under this Section 5.1(a) to use MSC Intellectual Property Rights, including the Program
Intellectual Property Rights owned by MSC outside the ViewRay Domain without the express written consent of MSC. 
 (b) The license granted
under Section 5.1(a) excludes the right to sublicense or otherwise practice the MSC Intellectual Property and the Program Intellectual Property owned by MSC for the purpose of making or having made Products except as otherwise provided under
Section 3.10. 
 (c) The license granted under this Section 5.1 shall be treated as a license of rights to “intellectual
property” (as defined in Section 101(56) of Title 11 of the United States Code, as amended (the “Bankruptcy Code”)) for purposes of Section 365(n) of the Bankruptcy Code. The parties agree that ViewRay may
elect to retain and may fully exercise all of its rights and elections under the Bankruptcy Code provided, that it abides by the terms of this Agreement. 

5.2 ViewRay Licenses. ViewRay hereby grants and agrees to grant to MSC, solely to provide the applicable services under this Agreement and to supply
Deliverables (during the Program) and Products (pursuant to Section 3) to ViewRay, a non-exclusive, paid-up and royalty-free license to use the ViewRay Intellectual Property and the Program Intellectual
Property owned by ViewRay in connection with its performance of the Program and its supply of Products pursuant to Section 3. Upon the expiration or termination of the applicable Program work, MSC’s license shall terminate and be of no
further force or effect. 
 5.3 Reservation of Rights. (a) This Agreement does not convey to ViewRay any ownership rights in any portion of any
MSC Intellectual Property or the Program Intellectual Property owned by MSC by implication, estoppel or otherwise, but constitutes only a license to use the MSC Intellectual Property and the Program Intellectual Property owned by MSC as necessary to
give effect to the license and in accordance with all of the terms of this Agreement. Title to the MSC Intellectual Property and the Program Intellectual Property owned by MSC, shall at all times remain vested in MSC. All rights in and to the MSC
Intellectual Property and the Program Intellectual Property owned by MSC not expressly granted under this Agreement are reserved to and retained by MSC. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 (b) This Agreement does not convey to MSC any ownership rights in any portion of the ViewRay
Intellectual Property or the Program Intellectual Property owned by ViewRay by implication, estoppel or otherwise. Title to the ViewRay Intellectual Property and the Program Intellectual Property owned by ViewRay shall at all times remain vested in
ViewRay. All rights in and to the ViewRay Intellectual Property and the Program Intellectual Property owned by ViewRay not expressly granted under this Agreement are reserved to and retained by ViewRay. 

(c) Title to and any interest in Program Intellectual Property described in clause (a) of the Program Intellectual Property definition
shall be the property of MSC. Title to and any interest in Program Intellectual Property described in clause (b) of the Program Intellectual Property definition shall be the property of ViewRay. Title to and any interest in Program Intellectual
Property described in clause (c) of the Program Intellectual Property definition shall be owned jointly by MSC and ViewRay; provided, that, except as set forth in subsection (e) below, ViewRay shall not use such jointly owned
Program Intellectual Property except in connection with the practice of the license granted under Section 5.1. 
 (d) For purposes of
this Agreement, except as otherwise set forth in this Agreement, the determination of as to which party invented any invention will be made in accordance with the standards of inventorship and conception under title 35 of U.S. Code and
title 37 of U.S. Code of Federal Regulations. 
 (e) During the term of this Agreement, each party shall promptly disclose to the other
in writing any Program Intellectual Property that might, under applicable law, be patentable or otherwise protectable. Program Intellectual Property (including, without limitation, improvements thereon whether developed by such party or any
employee, or agent of such party) will be added to Attachment 3c. Within forty five (45) days following the date of such disclosure regarding the existence of particular Program Intellectual Property (including, without
limitation, improvements thereon whether developed by a party or any employee or agent of such party) that is jointly owned, the parties shall confer and mutually agree as to appropriate protection for such Program Intellectual Property, including
an application, preparation, prosecution and maintenance strategy. If the parties cannot agree upon whether or not to seek patent or other protection with respect to any Program Intellectual Property that is jointly owned, the party desiring to seek
such protection may take whatever actions it deems necessary or appropriate to seek such protection in any and all jurisdictions deemed appropriate by such party at its cost and expense, and the other party shall assign to the party desiring to seek
such protection all right, title and interest in and to such Program Intellectual Property and shall cooperate and assist the party seeking such protection in such efforts at the cost and expense of the party seeking such protection; whereupon the
party to which such Program Intellectual Property has been assigned shall grant to the assignor thereof a non-exclusive, worldwide, irrevocable, paid-up, royalty-free, sub-licensable license: (i) if
ViewRay is the licensee, to make, have made, use, practice, offer to sell, sell and import, export and otherwise commercially exploit such Program Intellectual Property within the ViewRay Domain; and (ii) if MSC is the licensee, to make, have
made, use, practice, offer to sell, sell and import, export and otherwise commercially exploit such Program Intellectual Property outside of the ViewRay Domain. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 (f) MSC shall have the sole right, but not the obligation, to file, prosecute, and maintain, at
MSC’s sole expense, patents covering Program Intellectual Property owned solely by MSC. MSC shall promptly furnish or have furnished to ViewRay copies of all patents, patent applications, substantive patent office actions, and substantive
responses received or filed in connection with such applications (excluding patents and patent applications covering solely MSC Intellectual Property that is not licensed to ViewRay under Section 5.1). In the case of patent applications and
responses, copies will be furnished to ViewRay at least fifteen (15) days before filing or mailing, as the case may be. ViewRay may itself or through its attorney offer comments and suggestions with respect to the matters that are the subject
of this Section 5.3(f) and MSC agrees to consider such comments and suggestions; provided that nothing herein shall obligate MSC to adopt or follow such comments or suggestions. ViewRay shall cooperate in the preparation, filing, prosecution
and maintenance of any and all patent applications and patents covering Program Intellectual Property owned solely by MSC. MSC shall promptly provide notice to ViewRay as to all matters that come to its attention that may affect the preparation,
filing, prosecution or maintenance of any patents or patent applications covering Program Intellectual Property owned solely by MSC. In the event that MSC elects not to file for patent protection or elects not to prosecute or maintain a patent or
patent application in respect of Program Intellectual Property owned solely by MSC it shall notify ViewRay of such decision at least forty five (45) days prior to the due date of any action or payment due. ViewRay shall then have the right, but
not the obligation, to assume the responsibility therefor at its own cost and expense. 
 (g) ViewRay shall have the sole right, but not the
obligation, to prepare, file, prosecute, and maintain, at ViewRay’s sole expense, patents covering Program Intellectual Property owned solely by ViewRay. ViewRay shall promptly furnish or have furnished to MSC copies of all patents, patent
applications, substantive patent office actions and substantive responses relevant to the design or manufacturing practice of source shield, received or filed in connection with such applications. In the case of such patent applications and
responses, copies will be furnished to MSC at least fifteen (15) days before filing or mailing, as the case may be. MSC may itself or through its attorney offer comments and suggestions with respect to the matters that are the subject of this
Section 5.3(g) relating to the design or manufacturing practice of source shield and ViewRay agrees to consider such comments and suggestions; provided that nothing herein shall obligate ViewRay to adopt or follow such comments or
suggestions. MSC shall cooperate in the preparation, filing, prosecution and maintenance of any and all patent applications and patents covering Program Intellectual Property owned solely by ViewRay. 

5.4 Enforcement. (a) MSC shall be solely responsible for defense and enforcement of MSC Intellectual Property and Program Intellectual Property
owned by MSC, but in each case subject to the provisions of Section 5.4(b) with respect to enforcement within the ViewRay Domain. ViewRay shall be solely responsible for the defense and enforcement of ViewRay Intellectual Property and Program
Intellectual Property owned by ViewRay. 
  
 [***] Certain information in this document
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b) MSC shall have the first option to pursue any enforcement of MSC Intellectual Property and
Program Intellectual Property owned by MSC within the ViewRay Domain; provided, that MSC pays all costs and expenses’ related to the same, keeps ViewRay reasonably informed of its progress and provides ViewRay with copies of any
substantive documents related to such proceedings and reasonable notice of all such proceedings. MSC’s costs and expenses in prosecuting or defending such matters shall be subject to reimbursement in accordance with Section 5.4(d). MSC
shall notify ViewRay of its decision to exercise its right to enforce or defend such intellectual property within the ViewRay Domain not later than ninety (90) days following its discovery or receipt of notice of the alleged infringement. 

(c) If (i) MSC notifies ViewRay that it will not exercise its option to enforce any intellectual property in accordance with
Section 5.4(b); (ii) ViewRay and MSC have not otherwise agreed not to pursue or defend against such infringement for business reasons; (iii) MSC has not persuaded the alleged infringer to desist or the person alleging the infringement
to forebear, (iv) MSC is not diligently pursuing an infringement action or diligently defending the validity or enforceability of such intellectual property within the ViewRay Domain; or (v) MSC has not provided ViewRay with evidence of
bona fide negotiations of an acceptable sublicense agreement with the alleged infringer or person alleging infringement, then ViewRay shall have the right to pursue legal action against the alleged infringer or take control of any action initiated
by, or being defended by, MSC at ViewRay’s own cost and expense. 
 (d) Any recovery of damages in any suit handled by one party
pursuant to Section 5.4(b) or Section 5.4(c) shall be applied first in satisfaction of any unreimbursed expenses and legal fees of the party handling the suit or settlement thereof. The balance of any recovery obtained by settlement or
otherwise shall be distributed: (i) first to [***], and (ii) then to [***] (assuming [***]). The balance, if any, remaining after ViewRay and MSC have been compensated pursuant to
Section 5.4(d)(i)-(ii) shall be [***]. No settlement, consent judgment or other voluntary final disposition of any suit subject to Section 5.4(b) or Section 5.4(c) may be entered into without
the consent of the other party, which consent shall not be unreasonably withheld. 
 (e) In any infringement suit as either party may
institute to enforce Intellectual Property Rights covered by this Section 5.4, or in any declaratory judgment action alleging invalidity or non-infringement of any Intellectual Property Rights covered by this Section 5.4 brought against
MSC or ViewRay, the other party shall, at the request and expense of the party initiating or defending the suit or action, cooperate and assist in all reasonable respects, having its employees testify when requested and making available relevant
records, papers, information, specimens and the like. 
 6. CONFIDENTIALITY 

6.1 Publicity. The terms of this Agreement (including its existence) shall be treated as the Confidential Information of both parties and neither party
will issue any press release or make any other statement, written or oral, to the public, the press or otherwise, relating to this Agreement and the transactions contemplated by this Agreement that has not previously been approved in writing by the
other party. Nothing in this Section 6.1 shall prohibit a party from making such disclosures to the extent required under applicable federal or state securities laws or any rule or regulation of any nationally recognized securities exchange. In
such event, however, 
  
 [***] Certain information in this document has been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
the disclosing party shall use good faith efforts to notify and consult with the other party prior to such disclosure and, where applicable, shall diligently seek confidential treatment to the
extent such treatment is available under applicable securities laws. Each party may provide a copy of this Agreement or disclose the terms of this Agreement: (a) to any finance provider in conjunction with a financing transaction, if such
finance provider agrees to keep the terms of this Agreement confidential, (b) to enforce its rights under this Agreement in a proceeding in accordance with Section 10.2, (c) to any legal or financial advisor of such party, or
(d) to current/prospective investors provided such investors are subject to a confidentiality agreement that is consistent with the terms of Section 6.2 regarding protection of Confidential Information of the other party. 

6.2 Confidentiality. (a) Confidential Information of each party will be used by the other party solely for the purposes permitted by this
Agreement. All Confidential Information of a disclosing party will be received and held in confidence by the receiving party, subject to the provisions of this Agreement. Each party acknowledges that, except for the rights expressly granted under
this Agreement, it will not obtain any rights of any sort in or to the Confidential Information of the other party as a result of such disclosure and that any such rights must be the subject of separate written agreement(s). 

(b) Each party will restrict disclosure of the other party’s Confidential Information to those of its employees and consultants to whom
it is necessary or useful to disclose such Confidential Information in connection with the purposes permitted under this Agreement. Each party shall use reasonable efforts, including at least efforts commensurate with those employed by the party for
the protection of its own Confidential Information, to protect the Confidential Information of the other party. 
 (c) Nothing herein shall
prevent a receiving party from disclosing all or part of the Confidential Information of the other party in response to a court order or other legal proceeding requesting disclosure of same; provided, the party that receives such order or
process provides prompt notice to the disclosing party before making any disclosure (to the extent possible) and permits the disclosing party to oppose or narrow such request for disclosure and supports any of the disclosing party’s reasonable
efforts to oppose such request (at disclosing party’s expense), and only to the extent necessary to comply with such request. Disclosure of Confidential Information pursuant to this Section 6.2(c) will not alter the character of that
information as Confidential Information hereunder. 
 (d) Either disclosing party may at any time notify the receiving party that such
receiving party must return to the disclosing party the disclosing party’s Confidential Information. Each receiving party hereby agrees to, within thirty (30) days of such notification: (i) return all documents and tangible items it
or its employees or agents have received or created pursuant to this Agreement pertaining, referring or relating to the other party’s Confidential Information; and (ii) return or certify (in a writing attested to by a duly authorized
officer of such party) destruction of all copies, summaries, modifications or adaptations that such party or its employees or agents have made from the materials provided by the disclosing party; provided, however, that a party is permitted to
retain one copy of such materials in its legal files to be used to verify compliance with its obligations hereunder. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 7. REPRESENTATIONS AND WARRANTIES. 

7.1 Authorization; Enforceability. Each of ViewRay and MSC represents and warrants to the other party that: (a) it is duly organized and validly
existing under the laws of its jurisdiction of organization and has all requisite power and authority to enter into this Agreement; (b) it is duly authorized by all requisite action to execute, deliver and perform this Agreement and to
consummate the transactions contemplated hereby, and that the same do not conflict or cause a default with respect to such party’s obligations under any other agreement; (c) it has duly executed and delivered this Agreement; and
(d) it is authorized to disclose any and all Confidential Information made available to the other party pursuant to this Agreement. 
 7.2
Products. (a) MSC warrants to ViewRay that all Products supplied to ViewRay pursuant to Section 3 shall: (i) for a period of twelve (12) months from the date of acceptance by the ViewRay customer but not more than eighteen
(18) months from the date of shipment by MSC to ViewRay, whichever is longer, conform to its then current published specifications and documentation and the Specifications (provided that in the event of a conflict between the Specifications and
the published specifications or documentation, the terms of the Specifications will control), and (ii) be manufactured, labeled, packaged, stored and tested (while in the possession or control of MSC) in accordance with the Specifications
current as of the date of manufacture and the applicable laws and regulations in relation to the manufacture and testing of the Product (including all Applicable Standards). This warranty does not apply to any non-conformity of the Products
resulting from misuse, mishandling or storage in an improper environment in each case by any party other than MSC or its agents. 
 (b) MSC
warrants to ViewRay that all Products shall be delivered free and clear of all liens and encumbrances. 
 7.3 Remedy. In the event any Products
purchased by ViewRay from MSC fail to conform to the warranty set forth in Section 7.2, MSC shall, at MSC’s option, repair or replace the Products. ViewRay shall notify MSC of any such nonconformity and return the applicable Products in
accordance with Section 3.9. It is understood and agreed that the remedy set forth in this Section 7.3 shall not limit either party’s other remedies at law or equity, including a remedies with respect to third party claims arising
pursuant to Sections 8.2-8.3. 
 7.4 Disclaimer. (a) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS 7.1-7.2, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF
FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY MATTER WHATSOEVER, INCLUDING BUT NOT LIMITED TO, THE PRODUCTS. 
 (b) THE
REPRESENTATIONS AND WARRANTIES OF EACH OF MSC AND VIEWRAY EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED IN
SECTIONS 8.2-8.3. 
  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 8. RISK ALLOCATION 

8.1 Limitation of Liability. EXCEPT FOR BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER SECTION 6 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS 8.2-8.3 WITH RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR
EXEMPLARY DAMAGES IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, REGARDLESS OF WHETHER THE PARTIES HAVE ADVISED OR BEEN ADVISED OF THE POSSIBILITY OF ANY SUCH LOSS
OR DAMAGE. 
 8.2 Indemnification of View Ray. Subject to the provisions of Section 8.4, MSC will defend, indemnify, and hold harmless ViewRay
and its Affiliates, officers, directors, employees, agents, and their successors and assigns (each, in such capacity, an “ViewRay Indemnified Party”) from and against any claim, suit, demand, loss, damage, expense (including
reasonable attorneys’ fees of ViewRay Indemnified Party(ies) and those that may be asserted by a third party) or liability (collectively, “Losses”) arising from any third party claim or proceeding against the ViewRay
Indemnified Party(ies) by any third party to the extent that such claim or proceeding is based on: (a) a third party assertion that the Products infringe any third party Intellectual Property Rights; or (b) a third party allegation of
product liability or personal injury arising from or relating to a manufacturing defect of the Products. The foregoing indemnification action shall not apply in the event and to the extent that such Losses arose as a result of any ViewRay
Indemnified Party’s negligence, intentional misconduct or breach of this Agreement. 
 8.3 Indemnification of MSC. Subject to the
provisions of Section 8.4, ViewRay will defend, indemnify, and hold harmless MSC and its Affiliates, officers, directors, employees, agents, and their successors and assigns (each, in such capacity, an “MSC Indemnified
Party”) from and against any Losses arising from any third party claim or proceeding against the MSC Indemnified Party(ies) by any third party to the extent that such claim or proceeding is based on: (a) any third party allegation
of infringement of third party Intellectual Property Rights, where such claim is based upon the combination, operation or use of the Products with non-MSC technology and products in a manner not explicitly contemplated by this Agreement, if such
claim of infringement would have been avoided but for such combination, operation or use; or (b) any third party allegation of product liability or personal injury arising from or relating to the ViewRay products or services (other than due to
the failure of a Product due to nonconformance to the then current Specifications as manufactured by MSC, including MSC subcontractor/suppliers). The foregoing indemnification action shall not apply in the event and to the extent that such Losses
arose as a result of any MSC Indemnified Party’s negligence, intentional misconduct or breach of this Agreement. 
 8.4 Procedure. To receive
the benefit of indemnification under Section 8.2 or Section 8.3, the ViewRay Indemnified Party or MSC Indemnified Party, as applicable, must: (a) promptly notify the party from whom indemnification is sought (each, an
“Indemnifying Party”) of any claim or proceeding; provided, that failure to give such notice shall not relieve Indemnifying Party of its 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 
indemnification obligations except where, and solely to the extent that, such failure actually and materially prejudices the rights of Indemnifying Party; (b) provide reasonable cooperation
to the Indemnifying Party (and its insurer), as reasonably requested, at indemnifying Party’s cost and expense; and (c) tender to the Indemnifying Party (and its insurer) full authority to defend or settle the claim or suit;
provided that no settlement requiring any admission by the Indemnified Party or that imposes any obligation on the Indemnified Party shall be made without the Indemnified Party’s consent. Neither party has any obligation to indemnify the
other party in connection with any settlement made without the Indemnifying Party’s written consent. The Indemnified Party has the right to participate at its own expense in the claim or suit and in selecting counsel therefore. 

8.5 Insurance. Each party shall procure and maintain insurance, including product liability insurance, adequate to cover its obligations hereunder and
which are consistent with normal business practices of prudent companies similarly situated. It is understood that such insurance shall not be construed to create a limit of either party’s liability with respect to its indemnification
obligations under this Section 8. Each party shall cause the other to be listed as an additional named insured on such policy(ies) and shall provide the other with written evidence of such insurance upon request. Each party shall provide the
other with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance or self-insurance which materially adversely affects the rights of the other party hereunder. If such party does
not obtain replacement insurance or take other measures that allow it to provide comparable coverage within such 15-day period, the other party shall have the right to terminate this Agreement effective at the
end of such fifteen (15) day period without notice or any additional waiting periods. 
 9. TERM AND TERMINATION 

9.1 Term. This Agreement shall take effect as of the Effective Date and shall remain in effect until the |fifth| anniversary of the Effective Date (the
“Term”), unless sooner terminated in accordance with Section 2.5 or Section 9.2. Thereafter, this Agreement will renew automatically for additional one-year terms unless either party provides the other party with
written notice at least [twelve (12)] months in advance of the scheduled renewal date. 
 9.2 Termination. (a) During the term of the
Program, either party may terminate the Program and this Agreement upon thirty (30) days written notice to the other party if the other party commits a material breach of this Agreement, unless such breach is cured within the thirty
(30) day notice period, or if such breach is not capable of being cured within thirty (30) days unless such party during such thirty (30) day period initiates actions reasonably expected to cure the breach and thereafter diligently
proceeds to cure the breach. Except for termination by MSC based upon non-payment by ViewRay of amounts due under this Agreement, termination of the Program pursuant to this Section 9.2(a) shall not result in termination of this Agreement
except as otherwise provided in Section 9.2(c). The parties may also terminate the Program at any time in accordance with the procedure specified in Section 2.5. 

(b) Following completion of the Program and, with respect to matters not directly related to the Program at any time during or following
completion of the Program, either party may terminate this Agreement upon sixty (60) days written notice to the other party if the other party 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 
commits a material breach of this Agreement (other than non-payment), unless such breach is cured within the sixty (60) day notice period, or if such breach is not capable of being cured
within sixty (60) days unless such party during such sixty (60) day period initiates actions reasonably expected to cure the breach and thereafter diligently proceeds to cure the breach. 

(c) The parties may parties may terminate this Agreement at any time by mutual agreement. ViewRay may also terminate this Agreement in
accordance with Section 3.11(a). 
 (d) The disadvantaged party (as defined in Section 10.14) shall have the right to terminate
this Agreement upon thirty (30) days notice if a Force Majeure condition has prevented performance by the other party for more than sixty (60) consecutive days or an aggregate one hundred twenty (120) days in any 12-month period. 
 9.3 Effect of Termination. (a) Upon termination of the Program pursuant to
Section 9.2(a): (i) MSC will terminate all Program tasks then in process in art orderly manner, as soon as practical and in accordance with a schedule agreed to by ViewRay and MSC; (ii) MSC shall deliver to ViewRay a
reasonably-detailed written report describing the results of the Program up to the date of such termination; and (iii) ViewRay shall pay MSC any monies due and owing MSC as of the time of termination for work that has been actually performed
and, if such termination is made by MSC for cause under Section 9.2(a), ViewRay shall also pay MSC for all work-in process an amount calculated using MSC’s then-current daily charge for similar
services and Deliverables, provided, such fee shall not exceed the price specified for the applicable Deliverable in Attachment 1 against delivery of such work product by MSC. 

(b) Upon any termination (including expiration) of this Agreement each party shall return to the other party or certify in writing to the
other party that it has destroyed all documents and other tangible items it or its employees or agents have received or created pertaining, referring or relating to the Confidential Information of the other party; provided, that a party is
permitted to retain one copy of such materials in its legal files to be used to verify compliance with its obligations hereunder. 
 (c)
Upon termination or expiration of this Agreement for any reason, ViewRay will have the right to continue to sell all unsold Products that are in its possession or that are subject to an open ViewRay Purchase Order as of the effective date of such
termination or expiration. In addition, MSC will continue to supply ViewRay with Products for a period of [***] after expiration or termination of this Agreement for any reason to wind-down the supply of Products for ViewRay from MSC,
provided that if termination was effected by MSC as a result of ViewRay’s material breach of this Agreement then (i) ViewRay will promptly pay all sums due MSC under this Agreement as of the date of termination that are not disputed
in good faith in accordance with the procedure described in Section 10.2; and (ii) MSC may require that ViewRay place orders for Products (if any) ordered pursuant to this Section 9.3(c) on a C.O.D. basis. The supply of Products by
MSC pursuant to this Section 9.3(c) shall be subject to the provisions of 4-9 excluding [***]. 

(d) Nothing herein shall be construed to release either party of any obligation which matured prior to the effective date of any termination,
including the obligation of ViewRay to purchase all 
  
 [***] Certain information in
this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Products that are the subject of a binding Forecast as of the effective date of termination. Either party’s liability for any uncontested charges, payments or expenses due to the other party
that accrued prior to the termination date shall not be extinguished by termination, and such amounts (if not otherwise due on an earlier date) shall be immediately due and payable on the termination date. 

9.4 Survival. Sections 1, 2.1, 5-8, 9.3 (and the Sections of this Agreement referenced therein), 9.4 and
10 shall survive any termination or expiration of this Agreement. Section 2.2 shall survive any termination or expiration of this Agreement; provided that Section 2.2 shall not survive termination of this Agreement by ViewRay
pursuant to Section 9.1 or termination of the Program by the parties pursuant to Section 9.2(b). 
 10. GENERAL PROVISIONS. 

10.1 Governing Law. This Agreement shall be governed and construed in accordance with the internal, substantive laws of New York, to the exclusion of
any choice or conflict of laws rule or provision that would result in the application of the substantive law of any other jurisdiction. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement
or the transactions contemplated by this Agreement. 
 10.2 Dispute Resolution. (a) The parties will attempt to settle any claim or controversy
arising out of this Agreement or the subject matter hereof through consultation and negotiation in good faith in a spirit of mutual cooperation. Such matters will be initially addressed by the Manager of Hardware Development of ViewRay and the
Director of Manufacturing and Engineering of MSC, who shall use reasonable efforts to attempt to resolve the dispute through good faith negotiations by telephone or in person as may be agreed. In addition, all disputes brought by ViewRay will also
be copied to the MSC Manager of Contracts. If they fail to resolve the dispute within thirty (30) days after either party notifies the other of the dispute, then the matter will be escalated to the Senior Vice President of Engineering of
ViewRay and the President and General Manager of MSC, or their designees for resolution. They will use reasonable efforts to attempt to resolve the dispute through good faith negotiations by telephone or in person as may be agreed. If they fail to
resolve the dispute within thirty (30) days after it is referred to them and do not mutually agree to extend the time for negotiation, then the dispute will be submitted to arbitration in accordance with the procedure set forth in
Section 10.2(b). 
 (b) Except with respect to actions by either party seeking equitable or declaratory relief, any claim or
controversy arising in whole or in part under or in connection with this Agreement or the subject matter hereof that is not resolved pursuant to Section 10.2(a) will be referred to and finally resolved by arbitration in accordance with the
Commercial Arbitration Rules (the “Rules”) of the American Arbitration Association as such Rules may be modified by this Agreement, by one arbitrator, who will be agreed upon by the parties. If the parties are unable to agree
upon a single arbitrator within thirty (30) days following the date arbitration is demanded, three arbitrators will be used, one selected by each party within ten (10) days after the conclusion of the
30-day period and a third selected by the first two within 10 days thereafter. Unless the parties agree otherwise, they will be limited in their discovery to directly relevant documents. Responses or
objections to a document request will be served twenty (20) days after receipt of the request. The arbitrator(s) will resolve any discovery disputes. The foregoing arbitration 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
proceedings may be commenced by either party by notice to the other party. Unless otherwise agreed by the parties, all such arbitration proceedings will be held in Cleveland, Ohio or at
alternative location if mutually agreed, provided that proceedings may be conducted by telephone conference call with the consent of the arbitrator. All arbitration proceedings will be conducted in the English language and the arbitrator(s)
will apply the law of Delaware. The arbitrator(s) will only have the authority to award actual money damages (with interest on unpaid amounts from the date due) and, except with respect to a breach or nonperformance of any provision of this
Agreement relating to Confidential Information, the arbitrator(s) will not have the authority to award indirect, incidental, consequential, exemplary, special or punitive damages, and the parties expressly waive any claimed right to such damages.
The arbitration will be of each party’s individual claims only, and no claim of any other party will be subject to arbitration in such proceeding. The costs and expenses of the arbitration, but not the costs and expenses of the parties, will be
shared equally by the parties. If a party fails to proceed with arbitration, unsuccessfully challenges the arbitration award, or fails to comply with the arbitration award, the other party is entitled to costs, including reasonable attorneys’
fees, for having to compel arbitration or defend or enforce the award. Except as otherwise required by law, the parties and the arbitrator(s) will maintain as confidential all information or documents obtained during the arbitration process,
including the resolution of the dispute. Judgment on the award granted in any arbitration hereunder may be entered in any court having jurisdiction over the award or any of the parties or any of their respective assets. The provisions of this
Section 10.2(b) will not apply to any claim or controversy involving infringement or misappropriation of any Intellectual Property Right of either party, in which case the claim or controversy may be brought in a state or federal court having
jurisdiction over the matter. The parties knowingly and voluntarily waive their rights to have their dispute tried and adjudicated by a judge and jury except as expressly provided herein. 

10.3 Amendment and Waiver. No provision of or right under this Agreement shall be deemed to have been waived by any act or acquiescence on the part of
either party, its agents or employees, but only by an instrument in writing signed by an authorized officer of each party. No waiver by either party of any breach of this Agreement by the other party shall be effective as to any other breach,
whether of the same or any other term or condition and whether occurring before or after the date of such waiver. 
 10.4 Independent Contractors.
Each party represents that it is acting on its own behalf as an independent contractor and is not acting as an agent for or on behalf of any third party. This Agreement and the relations hereby established by and between ViewRay and MSC do not
constitute a partnership, joint venture, franchise, agency or contract of employment. Neither party is granted, and neither party shall exercise, the right or authority to assume or create any obligation or responsibility on behalf of or in the name
of the other party or its Affiliates. Each party shall be solely responsible for compensating all its personnel and for payment of all related FICA, workers’ compensation, unemployment and withholding taxes. Neither party shall provide the
other party’s personnel with any benefits, including but not limited to compensation for insurance premiums, paid sick leave or retirement benefits. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 10.5 Assignment. Neither party may assign this Agreement or any of its rights and obligations under this
Agreement without the prior written consent of the other party; provided, that either party may assign this Agreement without the consent of the other party to an Affiliate or in connection with any merger, acquisition, or sale a majority of
such party’s voting stock or a sale of substantially all such party’s assets; provided, further, that in each instance the assignee expressly assumes all obligations imposed on the assigning party by this Agreement in writing
and the other party is notified in advance of such assignment. Any purported assignment in violation of this Section 10.5 shall be null and void. 

10.6 Successors and Assigns. This Agreement shall bind and inure to the benefit of the parties hereto and their respective successors and permitted
assigns. 
 10.7 Notices. Unless otherwise provided herein, any notice, report, payment or document to be given by one party to the other shall be in
writing and shall be deemed given when delivered personally or mailed by certified or registered mail, postage prepaid (such mailed notice to be effective on the date which is three (3) Business Days after the date of mailing), or sent by
nationally recognized overnight courier (such notice sent by courier to be effective one (1) Business Day after it is deposited with such courier), or sent by telefax (such notice sent by telefax to be effective when sent, if confirmed by
certified or registered mail or overnight courier as aforesaid) to the address set forth on the signature page to this Agreement or to such other place as any party may designate as to itself by written notice to the other party. 

10.8 Severability. In the event any provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect,
such invalidity, illegality or unenforceability shall not affect any other term or provision hereof. The parties agree that they will negotiate in good faith or will permit a court to replace any provision hereof so held invalid, illegal or
unenforceable with a valid provision which is as similar as possible in substance to the invalid, illegal or unenforceable provision. 
 10.9
Captions. Captions of the sections and subsections of this Agreement are for reference purposes only and do not constitute terms or conditions of this Agreement and shall not limit or affect the meaning or construction of the terms and
conditions hereof. 
 10.10 Word Meanings. Words such as herein, hereinafter, hereof and hereunder refer to this Agreement as a whole
and not merely to a section or paragraph in which such words appear, unless the context otherwise requires. The singular shall include the plural, and each masculine, feminine and neuter reference shall include and refer also to the others, unless
the context otherwise requires. 
 10.11 Entire Agreement. The terms and provisions contained in this Agreement (including the Attachments)
constitute the entire understanding of the parties with respect to the transactions and matters contemplated hereby and supersede all previous communications, representations, agreements and understandings relating to the subject matter hereof. No
representations, inducements, promises or agreements, whether oral or otherwise, between the parties not contained in this Agreement shall be of any force or effect. No agreement or understanding extending this Agreement or varying its terms
(including any inconsistent terms in any purchase 
  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
order, acknowledgment or similar form) shall be binding upon either party unless it is in a writing specifically referring to this Agreement and signed by a duly authorized representative of the
applicable party. 
 10.12 Rules of Construction. The parties agree that they have participated equally in the formation of this Agreement and that
the language and terms of this Agreement shall not be construed against either party by reason of the extent to which such party or its professional advisors participated in the preparation of this Agreement. 

10.13 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Facsimile signatures shall be accepted as original signatures, orders may be transmitted electronically and any document created pursuant to this Agreement may be maintained in an electronic document storage
and retrieval system, a copy of which shall be considered an original. 
 10.14 Force Majeure. Except as otherwise provided in this Agreement, in the
event that a delay or failure of a party to comply with any obligation created by this Agreement is caused by acts of God, wars (declared or undeclared and including the continuance, expansion or new outbreak of any war or conflict now in
existence), revolution, civil commotion, acts of public enemy, labor strikes (other than employees of the affected party), terrorism, embargo or acts of government in its sovereign capacity (“Force Majeure”), the
“affected party” will, after giving prompt notice to the “disadvantaged party,” be excused from such performance on a day-to-day basis during the continuance of such prevention, restriction, or interference (and the disadvantaged
party will likewise be excused from performance of its obligations on a day-to-day basis during the same period), provided, however, that the affected party will use its best efforts to avoid or remove the causes of nonperformance and both parties
will proceed immediately with the performance of their obligations under this Agreement whenever the causes are removed or cease. If Force Majeure conditions continue for more than 60 consecutive days or an aggregate 120 days in any 12-month period, then the disadvantaged party may terminate this Agreement in accordance with Section 9.2(d). 

10.15 Further Assurances. Each party covenants and agrees that, subsequent to the execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and perform any acts which are or may become reasonably necessary to effectuate the purposes of this Agreement. 

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on their behalf by their duly authorized representatives intending it to take effect
as an instrument under seal as of the Effective Date. 
  
 [***] Certain information in
this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

									
	MANUFACTURING SCIENCES CORPORATION		VIEWRAY INCORPORATED
	By:    		 /s/ Brian C. Wood
				By:    		 /s/ Greg Ayers

	 Brian C. Wood, President and General Manager
				Greg Ayers, Acting Chief Executive Officer
			
	Notice Address: 				Notice Address:
	Manufacturing Sciences Corporation				ViewRay Incorporated
	804 South Illinois Avenue				#2 Thermo Fisher Way
	Oak Ridge, TN 37830				Oakwood Village, OH 44146

  

			
	 Attachment 1
		Specifications; Program
	 Attachment 2
		Pricing; Phases 1 and 2
	 Attachment 3a
		Certain MSC Intellectual Property
	 Attachment 3b
		Certain ViewRay Intellectual Property
	 Attachment 3c
		Program Intellectual Property

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Attachment 1 

Specifications; Program 
 MSC
Services: 
 ViewRay requires the development of a Product as specified in ViewRay Requirements Document
No.              (copy attached) which provides the detailed Specifications for each of the Deliverables. The development is [***]. 

 

					
	 Phase
	  	 Scope and Activities
	  	 Deliverables

	[***]	  	[***]	  	[***]

 Schedule: 
 It is
understood that an accelerated schedule is of great importance to ViewRay. With this in mind, the following schedule is planned for completion of each Phase of the Program: [***]. 

Pricing: See Attachment 2 for Phases 1 and 2. 

ViewRay’s responsibilities: 
 The following
shall be ViewRay’s responsibilities. 
 [***] 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 Attachment 2 

Program Pricing. ViewRay will pay to MSC a fixed sum of $[***] in consideration for MSC’s performance of the Program [***] and the delivery of the
Deliverables detailed in Attachment 1. Payment of such amount shall be made in installments against the following milestones, including where applicable the delivery and the Acceptance of Deliverables by ViewRay. Payment is
due in accordance with Section 2.7 except as otherwise provided below: 
  

					
	 Program Phase
	  	 Event; Deliverable
	  	 Program Payment

	 [***]
	  	[***]	  	[***]
	 Total
	  		  	$[***]

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Attachment 3a 

[***] 

Attachment 3b 

[***] 

Attachment 3c 

[***] 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.EX-10.12

 Exhibit 10.12 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 DEVELOPMENT AND SUPPLY AGREEMENT 

This Development and Supply Agreement (“Agreement”) is entered into as of July 9, 2009 (“Effective
Date”) by and between ViewRay Incorporated, a Delaware corporation with file number 4450114 and whose principal place of business is #2 Thermo Fisher Way, Oakwood Village, Ohio 44146, USA (“ViewRay”),
and Tesla Engineering Limited, a company organized under the laws of England with registered company number 02786571 and whose registered office is at Water Lane Industrial Estate, Storrington, West Sussex RH20 3EA
(“Tesla”). 
 Background 

ViewRay possesses valuable knowledge, expertise, intellectual properties and resources with regard to high performance radiation oncology devices. Tesla
possesses valuable knowledge, expertise, intellectual properties and resources with regard to gradient coil devices for use in radiology applications. 

ViewRay wishes to engage Tesla to develop a gradient coil device which will meet certain agreed technical specifications for incorporation into ViewRay’s
RenaissanceTM radiation therapy system. ViewRay also wishes to purchase from Tesla quantities of such gradient coil device. 
 Tesla is willing to
provide ViewRay with development services for this device and is also willing to sell ViewRay quantities of such device at favorable pricing in exchange for ViewRay’s agreement to maintain exclusivity of supply during a specified period. 

NOW THEREFORE, the parties agree as follows with respect to such development and supply arrangements. 

1. DEFINITIONS. 
 1.1 Defined Terms. Capitalized
terms used in this Agreement and not otherwise defined herein shall have the meaning set forth below. 

“Affiliate” means with respect to either party, any Person that, directly or indirectly, is controlled
by, controls or is under common control with such party. For purposes of this definition only, “control” means, with respect to any Person, the direct or indirect ownership of more than fifty percent (50%) of the voting
or income interest in such Person or the possession otherwise, directly or indirectly, of the power to direct the management or policies of such Person. 

“Applicable Laws” means all applicable laws, statutes, regulations and ordinances. 

“Business Day” means any day other than a Saturday or Sunday that is not a national holiday in the
United States or the United Kingdom. 
 “Commercially Reasonable Efforts” means
(i) with respect to any objective by any party, commercially reasonable, diligent, good faith efforts to accomplish such objective as such party would normally use to accomplish a similar objective under similar circumstances; and
(ii) with respect to any objective relating to the development or commercialization of any product by any party, efforts and resources normally used by such party with respect to a product owned by such party at a similar stage in the
development or life of such product. 

 “Confidential Information” means any proprietary or
confidential information of either party (including but not limited to all ViewRay Intellectual Property and all Tesla Intellectual Property) disclosed to the other party pursuant to this Agreement, except any portion thereof which: (i) is
known to the receiving party, as evidenced by the receiving party’s prior written records, before receipt thereof under this Agreement; (ii) is disclosed to the receiving party by a third person who is under no obligation of
confidentiality to the disclosing party hereunder with respect to such information and who otherwise has a right to make such disclosure; (iii) is or becomes generally known in the public domain through no fault of the receiving party; or
(iv) is independently developed by the receiving party, as evidenced by the receiving party’s written records, without access to such information. 

“Control or Controlled” means, with respect to any Intellectual Property Right, the possession (whether
by ownership, license, or other agreement or arrangement existing now or after the Effective Date, other than pursuant to this Agreement) by a party or an Affiliate thereof of the right to grant to the other party a license as provided herein under
such Intellectual Property Right without violating the terms of any agreement or other arrangement of such party or its Affiliate with any third party. 

“FCA” means “Free Carrier (named place)”, as that expression is defined in Incoterms
2000, ICC Publishing S.A. 
 “Intellectual Property Right(s)” means all rights in
(1) U.S. and foreign utility and/or design patents, patent applications, and utility models; (2) patents issuing on the patent applications described in clause (1); (3) continuations, continuations-in-part, divisions, reissues,
reexaminations, or extensions of the patents or applications described in clauses (1)-(2); (4) inventions, invention disclosures and improvements, whether or not patentable; (5) works of
authorship, whether or not protectable by copyright, all copyrights to such works, including all copyright registrations and applications and all renewals and extensions thereof; (6) rights in industrial designs; (7) trade marks, trade
names and domain names, rights in get-up, rights in goodwill or to sue for passing off, and (8) trade secrets, Confidential Information, know-how, processes, algorithms, proprietary databases, and other
proprietary information, and all tangible and intangible embodiments thereof. 

“Person” means any individual, corporation, association, partnership (general or limited), joint
venture, trust, estate, limited liability company, limited liability partnership, unincorporated organization, government (or any agency or political subdivision thereof) or other legal entity or organization, other than Tesla or ViewRay.

 “Product” means a gradient coil that can be incorporated in the magnetic resonance imaging
subsystem of the ViewRay RenaissanceTM radiation therapy system. 
 “Program” means
the development program described in Attachment 1. The Program commenced on or around March 1, 2009. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 “Program Intellectual Property” means, individually and
collectively, all Intellectual Property Rights that are conceived, created, discovered, developed, generated, made or reduced to practice or fixed in a tangible medium of expression as part of or based upon or related to activities undertaken as
part of the Program whether: (a) solely by one or more employees or agents of Tesla; (b) solely by one or more employees or agents of ViewRay; or (c) jointly by one or more employees or agents of Tesla and one or more employees or
agents of ViewRay. Program Intellectual Property will be listed in Attachment 4, which shall be amended from time-to-time to include new Program Intellectual Property, in accordance with
Section 5.3. 
 “Specifications” means the specifications for the Product set forth
in Attachment 1, as they may be amended or supplemented by the parties pursuant to Section 2.4. 

“Tesla Intellectual Property” means, individually and collectively, all Intellectual Property Rights
that are conceived, discovered, developed, generated, created, made or reduced to practice or fixed in a tangible medium of expression by employees or consultants of Tesla at any time prior to the Effective Date or after the Effective Date if such
Intellectual Property Rights are not based upon or related to the performance of the Program. The term Tesla Intellectual Property, however, does not include any know-how, processes, information and data which is, as of the Effective Date or later
becomes, generally available to the public through no breach by ViewRay of its obligations under this Agreement. Tesla Intellectual Property that exists as of the Effective Date includes the Intellectual Property Rights described in
Attachment 4A. 
 “ViewRay Domain”
means the [***]. 
 “ViewRay Intellectual Property” means, individually and
collectively, all Intellectual Property Rights that are conceived, discovered, developed, generated, created, made or reduced to practice or fixed in a tangible medium of expression solely by employees or consultants of ViewRay at any time prior to
the Effective Date or after the Effective Date if such Intellectual Property Rights are not based upon or related to the performance of the Program. The term ViewRay Intellectual Property, however, does not include any know-how, processes,
information and data which is, as of the Effective Date or later becomes, generally available to the public through no breach by Tesla of its obligations under this Agreement. ViewRay Intellectual Property that exists as of the Effective Date
includes the Intellectual Property Rights relating to gradient coil design described in Attachment 4B. 

1.2 Other Defined Terms. The following terms shall have the meanings set forth in the section appearing opposite such term: 

 

			
	 “Acceptance”
		Section 2.3
	 “Act”
		Section 4.1
	 “AER”
		Section 4.3
	 “affected party”
		Section 10.14
	 “Agreement”
		Recitals
	 “Applicable Standards”
		Section 4.1
	 “Bankruptcy Code”
		Section 5.1
	 “Change Control Document”
		Section 2.4

  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

			
	 “Change Request”
		Section 2.4
	 “Deliverable(s)”
		Section 2.3
	 “Deposit Materials”
		Section 3.10
	 “disadvantaged party”
		Section 10.14
	 “Effective Date”
		Recitals
	 “Escrow Agent”
		Section 3.10
	 “Escrow Agreement”
		Section 3.10
	 “FDA”
		Section 4.2
	 “Force Majeure”
		Section 10.14
	 “Forecast”
		Section 3.2
	 “Full Production”
		Section 3.2
	 “Indemnifying Party”
		Section 8.4
	 “ISO”
		Section 4.1
	 “Losses”
		Section 8.2
	 “MDR”
		Section 4.3
	 “Net Sales”
		Section 5.5
	 “Purchase Order”
		Section 3.3
	 “Regulatory Authority”
		Section 4.2
	 “Response Period”
		Section 2.4
	 “RMA”
		Section 3.9
	 “Rules”
		Section 10.2
	 “SOPS”
		Section 4.3
	 “Term”
		Section 9.1
	 “Tesla”
		Recitals
	 “Tesla’s Cost of Goods Sold”
		Section 3.5
	 “Tesla Indemnified Party(ies)”
		Section 8.3
	 “ViewRay”
		Recitals
	 “ViewRay Indemnified Party(ies)”
		Section 8.2.

 2. DEVELOPMENT PROGRAM 

2.1 Development of Product. The Program is directed toward the development of a Product that meet the applicable Specifications set forth in
Section A of Attachment 1 (including the documents referenced therein) and is expected to have a duration of twelve (12) months. It is understood and agreed that Tesla will use its Commercially Reasonable Efforts
to complete the Program and deliver a Product that meets the applicable Specifications; delivering a detailed design for the Product that satisfies the Specifications detailed in Section A of Attachment 1 within six
(6) months after the Effective Date and delivering a prototype Product that satisfies the Specifications detailed in Paragraph 2 of Attachment 1 within nine (9) months after the Effective Date. 

2.2 Progress Reports. (a) ViewRay and Tesla shall periodically meet, in person or by telephone or videoconference at such times and places as are
mutually agreed upon, for Tesla to provide ViewRay with an update on the status of the progress of the Program. ViewRay and Tesla shall each be responsible for its own expenses incurred in connection with attending such meetings. The parties’
representatives for purposes of meetings under this Section 2.2 will be Tesla’s Operations Director, or closest equivalent existing at the time, and ViewRay’s Director of MRI Engineering, or closest equivalent existing at the time.

  
 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b) Tesla shall provide ViewRay in advance of each meeting pursuant to Section 2.2(a) an
agenda for such meeting and reasonably-detailed written reports describing the results of the Program, including difficulties encountered in achieving the technical objectives of the Program during the period since their last meeting. It is
understood and agreed that neither party may change the Specifications without the consent of the other party using the procedure set forth in Section 2.4. 

2.3 Deliverables. (a) Tesla shall deliver each deliverable due under Attachment 1 (each, a
“Deliverable”) to ViewRay’s Oakwood Village, Ohio facility in accordance with the schedule in Attachment 1. Prior to shipment ViewRay shall inspect the Deliverable and test such Deliverable
against the applicable Specifications which may include installation and imaging with the Deliverable at Tesla’s facility. If ViewRay accepts the Deliverable, ViewRay shall acknowledge its acceptance (“Acceptance”) of
the Deliverable in writing. If ViewRay rejects the Deliverable, ViewRay shall provide Tesla with notice of rejection, including a reasonably specific description of the deficiencies alleged. Tesla will use Commercially Reasonable Efforts to cure any
such deficiencies in an expedient manner and either “re-deliver” such Deliverable to ViewRay within ten (10) Business Days following the notice of rejection or, if Tesla cannot accomplish such re-delivery within such 10-Business Day period deliver to ViewRay within such 10-Business Day period a plan for curing said
deficiencies. If Tesla makes re-delivery of the Deliverable, ViewRay shall, following its receipt of the re-delivered Deliverable, accept or reject the Deliverable using
the procedure specified above. If Tesla instead provides a correction plan for such Deliverable, ViewRay shall within five (5) Business Days following receipt of such correction plan either agree to, offer modifications of or reject said
correction plan. The parties shall repeat the above process until the earlier of the date that a mutually acceptable correction plan is agreed or thirty (30) Business Days following ViewRay’s notice of rejection. If the parties are unable
to agree on a mutually acceptable correction plan, and do not extend the timeframe for reaching an accepting a mutually acceptable plan, then ViewRay may terminate this Agreement and ViewRay will “return” the Deliverable to Tesla and Tesla
shall, within thirty (30) days following receipt of the rejected Deliverable, return to ViewRay all sums (if any) paid by ViewRay to Tesla for the Deliverable that is the subject of such rejection (but shall not be required to return the
funding provided pursuant to Paragraph 1 of Attachment 2 through the date of termination). If the parties do agree upon a correction plan, then Tesla shall perform such correction plan and “re-deliver” the Deliverable within the agreed time period. ViewRay shall, following its receipt of the re-delivered Deliverable, accept or reject the Deliverable
using the procedure specified above. The process specified in this Section 2.3 shall be repeated until the earliest of the date: (i) ViewRay accepts the re-delivered Deliverable; or (ii) ViewRay
rejects the Deliverable two (2) times for failure to comply with the Specifications; or (iii) one hundred eighty (180) days elapses from the initial notice of rejection. If the parties are unable to resolve such nonconformity within
such time period, then ViewRay may terminate this Agreement and ViewRay may “return” the Deliverable to Tesla and Tesla shall, within thirty (30) days following receipt of the rejected Deliverable, return to ViewRay all sums (if any)
paid by ViewRay to 
  
 [***] Certain information in this document has been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Tesla for the Deliverable that is the subject of such rejection (but shall not be required to return the funding provided pursuant to Paragraph 1 of Attachment 2
through the date of termination. For the avoidance of doubt all inspection, testing and Acceptance of the Deliverables by ViewRay shall occur at Tesla’s facility prior to shipment. 

(b) It is understood and agreed that the Deliverables [***] for ViewRay to make payment of the progress payments (if any) specified in
Attachment 2, but if any Deliverable delivery or redelivery [***] in accordance with the [***], ViewRay [***] such Deliverable delivery or redelivery. Notwithstanding the foregoing, Acceptance will not relieve Tesla of its
obligation to [***]. ViewRay’s obligations to pay for the Deliverables are subject to Acceptance, ViewRay shall have no obligation to pay for Deliverables except to the extent they are the subject of ViewRay’s Acceptance. 

(c) ViewRay will use Commercially Reasonable Efforts to test each Deliverable as quickly as practicable and in any event within thirty
(30) days of “delivery” of such Deliverable. 
 2.4 Changes. (a) During the Program, ViewRay may request amendments to
Attachment 1 to effect changes in the Specifications. If ViewRay wishes to make a change it shall notify Tesla of the requested change specifying the change with sufficient details to enable Tesla to evaluate it (a
“Change Request”). Within ten (10) Business Days following the date of Tesla’s receipt of a ViewRay Change Request, Tesla shall deliver a document that: (i) assesses the impact of the change on the schedule,
and (ii) incorporates a description of the requested change and the cost therefor (a “Change Control Document”). 

(b) Within ten (10) Business Days following ViewRay’s receipt of a Tesla Change Control Document (“Response
Period”), ViewRay will notify Tesla whether or not it accepts the Change Control Document. If ViewRay accepts the Change Control Document, then the provisions of this Agreement shall be deemed amended to incorporate such change
in accordance with the Change Control Document. If ViewRay notifies Tesla not to proceed within the Response Period, then the Change Request shall be deemed withdrawn and Tesla shall take no further action in respect of it. If Tesla has not received
any notice by the expiration of the Response Period, then ViewRay shall be deemed to have advised Tesla not to proceed. A separate Change Control Document will be required for each Change Request but a Change request may include multiple
changes; and each Change Control Document will become subject to this Agreement when signed by Tesla and ViewRay. 
 (c) Tesla
may not make any changes in the form, fit, function, design, manufacturing process, manufacturing location or appearance of the Products or the Specifications without ViewRay’s prior written approval, which shall not be unreasonably withheld.
Tesla may recommend amendments to Attachment 1 to effect changes in the Specifications if necessary to respond to difficulties encountered in achieving the technical objectives of the Program. If Tesla wishes to recommend a
Change Request, it shall notify ViewRay of the requested change and provide ViewRay with a Change Control Document and the provisions of Section 2.4(a)-(b) shall apply. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (d) It is the intent of the parties that the Specifications have been defined broadly enough and
with sufficient detail to accomplish ViewRay’s goal for the Product without price increases even if the services are changed pursuant to this Section 2.4; provided that such changes, as documented in a Change Control Document, do
not change the scope of the tasks contemplated by the Specifications. 
 2.5 Success Criteria. If the Product prototype delivered in Phase 2 of
the Program meets the applicable Specifications, then the provisions of Section 3 shall take effect. If the Product prototype delivered in Phase 2 of the Program does not meet the Specifications or if ViewRay and Tesla determine
during the course of the Program that the results of the Program are unsatisfactory; which determination shall be made with reference to the prospects for realizing Products that meet the Specifications then in each case they may mutually agree to
terminate the Program under Section 9.2(b). If the parties do not agree with respect to termination of the Program, they shall resolve such dispute using the procedure specified in
Section 10.2(a)-(b). 
 3. PURCHASE OF PRODUCTS AND TERMS OF SALE 

3.1 Supply. If the Products meet the Specifications then ViewRay will purchase from Tesla during the period ending on the fifth anniversary of the
Effective Date ViewRay’s requirements for the Products. 
 3.2 Purchase Forecasts. At least [***] prior to the first delivery to
ViewRay of commercial Products, ViewRay will deliver to Tesla a [***] rolling forecast (the “Forecast”). The Forecast will cover the [***] commencing with and including the calendar month in which the first delivery of
Products is to occur. After delivery of the initial Forecast, the Forecast will be updated on a [monthly] basis. During the period prior to the date when ViewRay Product demand (as measured by units of Product received by ViewRay) averages
[***] or more Products per month over a [***] period the Forecast shall be non-binding until [***] prior to the forecast shipment date at which time the quantities become binding on ViewRay. Thereafter (the “Full Production
Period”) the Forecast shall be non-binding until [***] prior to the forecast shipment date at which time the quantities become binding on ViewRay. 

3.3 Product Orders. ViewRay will submit to Tesla firm written purchase orders (each a “Purchase
Order”) for the purchase of Products at least [***] to the specified delivery date of the ordered Products. Each Purchase Order will specify the quantity or, if more than one shipment is requested, quantities of Products ordered, the
requested delivery date or dates, and ship-to locations. Orders will be placed by ViewRay to Tesla by email or facsimile, or by other means agreed upon by the parties, to an address provided by Tesla, which
will initially be, [***] copied to [***]. In the case of conflict between the provisions of this Agreement and either the standard printed terms of any Purchase Order or the standard printed terms of sale of Tesla, the provisions of this Agreement
will control. Purchase Orders [***], but ViewRay may [***]. 
 3.4 Acceptance; Obligation to Supply. (a) Tesla will acknowledge
all Purchase Orders within five (5) Business Days following receipt of same and will deliver all orders per the P.O. delivery dates so long as those delivery dates are consistent with the forecasted delivery schedule with any modifications per
section 3.3. In the event that the P.O. specifies delivery dates which are inconsistent with the forecast and reschedule delivery provisions of 3.3, Tesla will notify 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 
ViewRay of said discrepancy within five (5) Business Days following receipt of same along with best available dates for said product. Tesla will accept all Purchase Orders for a particular
calendar month to the extent that the Purchase Order (i) is consistent with the forecast and rescheduling provisions of section 3., and (ii) requires delivery no less than sixty (60) days following the date on which Tesla
receives the Purchase Order. Tesla will not be in breach of this Section 3.4 if Tesla’s failure to supply Products is due to a Force Majeure event or if Tesla’s failure is limited to quantities in excess of the quantities specified in
the binding Forecast period. 
 (b) Each party will promptly notify the other party of any circumstances that it believes may be of
importance as to Tesla’s ability to meet ViewRay’s needs for the Products in a timely manner. If the Forecasts indicate that ViewRay’s need for the Products will exceed Tesla’s existing capacity to supply the Products, the
parties will determine in good faith whether Tesla successfully can expand its production capacity so as to meet ViewRay’s needs in a timely manner. 

3.5 Pricing. (a) The prices for the Products supplied to ViewRay pursuant to this Section 3 shall be
agreed by the parties not later than [***] following the Effective Date; provided, that if the parties cannot agree upon pricing for the Products within such period, then the pricing shall be fixed at Tesla’s Cost of Goods Sold for such
Products plus [***] percent ([***]%)]. “Tesla’s Cost of Goods Sold” shall mean the [***] (including [***] of said Product) plus [***] allocated to the Product in accordance with [***]. The cost of Tesla’s
[***]. Tesla will adjust the [***] of the [***] to reflect [***] by the [***] for the most recent [***]. 
 (b) If the pricing
for Products is based upon Tesla’s Cost of Goods Sold then Tesla shall provide ViewRay upon request with back-up cost information for cost components for [***]. 

(c) Once Full Production levels are achieved, the pricing of Products, if [***], will be subject to a [***] the terms of which will be
specified at the time of the agreed pricing and will be attached as Paragraph 8 of Attachment 2. 
 3.6
Payment. (a) All payments under this Section 3 will be made by check or wire transfer. Payments will be made in US Dollars as indicated in this Agreement or in another currency by mutual agreement of the parties. All amounts due under
this Section 3 will be due within forty five (45) days of receipt of invoice. Tesla will invoice ViewRay upon shipment. 
 (b) If
ViewRay fails to make any payment due to Tesla under this Agreement by the due date for payment, then, without limiting Tesla’s remedies under Section 9.2, the overdue amount shall accrue interest at the rate of [***]% per annum [***] for
the due date from the due date until the date of actual payment of the overdue amount. This Section 3.6(b) shall not apply to payments that ViewRay contests in good faith using the procedures in Section 10.2 during the pendency of such
dispute; provided that in the event ViewRay does not prevail in such dispute then [***] from the [***]. 
 3.7 Resale Prices. Nothing
contained herein shall be deemed to limit in any way the right of ViewRay to determine the prices at which, or the terms on which, the Products purchased by ViewRay may be resold by ViewRay as part of ViewRay products or services. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 3.8 Shipping. Tesla shall arrange for shipment and invoicing to ViewRay of the Products ordered by ViewRay
via common carrier, FCA Tesla’s facility. ViewRay shall pay all transportation, customs, duties and other governmental charges, if any, relating to the importation and sale of the Products, and shall have all responsibility for storing and
clearing the Products through all customs and importation requirements. 
 3.9 Defective Product. (a) Tesla
will at its expense and at no further cost to ViewRay replace Products that do not conform to the applicable warranties specified in Section 7.2 during the applicable warranty period specified therein using the procedure specified in this
Section 3.9. ViewRay will notify Tesla in writing of any alleged defect of Product, will request a Return Material Authorization (“RMA”) number and will within 30 days of receipt of such RMA number return such
Product to Tesla freight prepaid and properly insured, along with a reasonably detailed statement of the claimed defect and proof of date of purchase. Such notice and statement may be sent to an email address provided by Tesla, which will initially
be [***] with a copy to [***]. Tesla will use Commercially Reasonable Efforts to deliver replacement Product to ViewRay or its designated customer freight prepaid and properly insured with earliest delivery which can be obtained
subject to sub Tesla and/or Tesla availability of said parts; provided, that for those Product components that are the subject of Section 3.9(b), ViewRay may elect to use the procedure described in Section 3.9(b) to replace the
applicable Product components. In the event that Tesla reasonably determines that any allegedly nonconforming Product is in fact not defective (including Product that has been modified, misused, abused or the subject of unauthorized repair), Tesla
will notify ViewRay in writing and ViewRay will [***] related to the [***], the [***], and the [***] (if applicable). ViewRay will only return Products to Tesla with Tesla’s prior written approval. If ViewRay disputes Tesla’s determination
that a Product is not defective, the dispute will be discussed and resolved using the procedure provided in Section 10.2. 
 3.10
Manufacturing Rights. (a) If Tesla fails to supply Product ordered by ViewRay in accordance with the Section 3.3, in accordance with the terms of this Agreement regarding the quantity or quality of Products supplied to ViewRay, then
Tesla shall use Commercially Reasonable Efforts to remedy the problem or secure an alternative source of supply within [***] at no cost to ViewRay, and any such alternative source of supply shall be on terms substantially identical with the terms of
this Agreement. If Tesla is unable to remedy the problem or secure an alternative source of supply within [***] after its initial failure to supply, then Tesla shall consult with ViewRay and the parties shall work together to remedy the problem. If
Tesla is unable to remedy the supply problem after [***] (or longer as agreed in writing by the parties), commencing with the date upon which such failure to supply began, then ViewRay may at its option, and upon notice to Tesla, manufacture the
Products itself or through a third party in accordance with the provisions of Section 3.10(b). 
 (b) If ViewRay notifies Tesla that
ViewRay will manufacture the Products itself or through a third party, then: (i) ViewRay shall [***] necessary to manufacture Products that conform to the Specifications; and (ii) Tesla shall (1) cooperate with ViewRay to cause the
release of the Deposit Materials (as defined in Section 3.10(c)); and (2) provide ViewRay or its designee, upon request, with reasonable assistance in establishing a back-up manufacturing line,
having 
  
 [***] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
reference to Tesla’s then existing resources. ViewRay shall [***]. ViewRay shall require any third party ViewRay designates to manufacture Products pursuant to this Section 3.10, to
agree in writing to observe the terms of this Agreement relating to confidentiality and the manufacture of Products. It is understood and agreed that ViewRay’s access to Deposit Materials pursuant to this Section 3.10(b) is conditional
upon [***] (and [***] necessary to manufacture Products that conform to the Specifications) as provided in Section 3.10(c). 

(c) On the Effective Date or as soon as is reasonably practicable thereafter, the parties shall enter into a escrow agreement
(the “Escrow Agreement”) with [***] (the “Escrow Agent”) containing terms acceptable to the parties and the Escrow Agent. The Escrow Agreement shall provide, among other provisions, that Tesla shall
deposit within forty (40) Business Days following the date that the design for the Products is completed (estimated to be within six months after the Effective Date) and maintain in escrow information necessary to enable ViewRay or its designee
to manufacture Products conforming with the Specifications (and any enhancements, modifications, upgrades, corrections, and components to the Product developed during the term of this Agreement), including any drawings, manufacturing instructions,
testing equipment vendors (and detailed modification notes for any modifications made to such testing equipment for purposes of testing the Products) equipment settings, supply chain information, costed bills of materials, testing procedures, or
other information as well as any manuals, programmers notes, and other materials needed to access and use such materials (collectively, the “Deposit Materials”). The escrow described in this Section 3.10(c) will be
created and maintained [***]. The Deposit Materials shall be released to ViewRay in accordance with the terms of the Escrow Agreement, in the event that: (i) Tesla is in breach of its obligations under this Agreement and fails to cure such
breach within the time period set forth in Section 9.2, and then upon the date such cure period has elapsed; or (ii) Tesla makes a general assignment for the benefit of its creditors or a receiver or administrative receiver is appointed
over any of Tesla’s assets, or an order is made or any petition is presented (other than a petition which is discharged within 60 days of its presentation and before it is advertised) by Tesla, any creditor or otherwise, for the winding
up, dissolution, liquidation or reconstruction of Tesla or for the making of an administration order in relation to Tesla or the freezing or other attachment of Tesla’s assets, or any resolution is passed for the voluntary winding up of Tesla;
or any proceeding or step analogous to any of the foregoing events or circumstances described in this Section 3.10(c)(ii) is taken in any jurisdiction, and then upon the occurrence of such event or circumstances, save in the case of the
presentation of a petition when the Deposit Materials shall be released to ViewRay upon the day on which the 60 day period following such presentation has elapsed without discharge PROVIDED THAT ViewRay shall not seek release of the Deposit
Materials from the Escrow Agent pursuant to this Section 3.10(c)(ii) in the event and for so long as Tesla or any liquidator, administrator, receiver or administrative receiver or trustee in control of Tesla’s assets continues to perform
(or cause Tesla to perform) Tesla’s obligations under this Agreement. A copy of the Escrow Agreement is attached as Attachment 3. 

(d) Upon release of the Deposit Materials in accordance with the Escrow Agreement, Tesla hereby grants ViewRay a limited, non-exclusive,
license to use, reproduce, and modify the Deposit Materials as necessary to manufacture (or have manufactured on its behalf by a third party) the Products. The Deposit Materials will be treated as Confidential Information of Tesla 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
and ViewRay will restrict disclosure of the Deposit Materials to those of its employees to whom it is necessary to disclose such Confidential Information in connection with the performance of
their duties hereunder. Receipt by ViewRay of the Deposit Materials pursuant to this Section 3.10 does not convey title or ownership of the Deposit Materials, which shall remain with Tesla and all Deposit Materials will continue to be treated
as Tesla Confidential Information following the release thereof. 
 3.11 Changes. (a) The Product Specifications for “commercial”
Product supplied pursuant to this Section 3 may be modified or changed only by ViewRay. ViewRay shall use the procedure specified in Section 2.4(a)-(b) to request such modifications or changes,
except as modified in this Section 3.11. To the extent that any such modification or change results in an increase or decrease in the cost of manufacturing any Product or requires additional capital investment or other material changes to the
manufacturing process, the parties shall jointly examine and mutually agree upon the consequences thereof and shall make an appropriate increase or decrease to the purchase price of such Product arising from such modification or change. In the event
that any such change or modification results in the obsolescence of any raw materials, work-in-process, and/or finished materials, the cost of any such obsolescence shall be the sole responsibility of ViewRay to a maximum of [***] of the change
date. At least [***] prior notice is required for any requested Product Specifications change pursuant to this Section 3.11; provided, however, that if any requested Product Specifications change requires additional regulatory approval(s), the
implementation of such requested change shall in no event be required until [***] after such approval(s) have been obtained. Tesla shall not be required to implement any change to the Product Specifications that it reasonably believes will prevent
it from being able to perform in accordance with the terms of this Agreement unless such terms are modified. If Tesla notifies ViewRay that it believes the preceding sentence is applicable the parties shall meet and attempt to resolve the matter
within ninety (90) days using the procedure specified in Section 10.2 if necessary; during any such period the Product will continue to be manufactured under the Product Specifications without such modification. If the parties are unable
to resolve such matter within such 90-day period, then ViewRay may terminate this Agreement in accordance with Section 9.2(b) and Tesla shall continue to supply the Product to ViewRay under the Product
Specifications without such modification for a period of up to [***] using the procedure specified in Section 9.3(c). 
 (b) Tesla will
not alter, modify, add to, or otherwise change the Product Specifications, Product, or any materials, suppliers or manufacturing techniques used in the design or production of the Products that will or may possibly effect the form, fit or function
of the Products without ViewRay’s prior written approval. ViewRay may require Tesla to make changes in raw materials or processes subject to a mutually agreed price adjustments. Tesla may rebalance its production line in its reasonable business
judgment; provided that the rebalancing makes no change to and has no effect on the form, fit or function of the Products. ViewRay will not make any changes to the Product Specifications without notifying Tesla in accordance with section
3.11(a). 
  
 [***] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 4. QUALITY ASSURANCE; SUPPORT 

4.1 Manufacturing Practices; Testing. Tesla shall manufacture the Products supplied pursuant to Section 3 in
accordance with the quality standards set out in Attachment 5 and the Specifications. Tesla will install and maintain effective quality control systems, conduct quality assurance testing and keep comprehensive process control records conforming
to (1) standards provided or approved by ViewRay and comparable to such process or processes conducted by ViewRay at its factory for its own similar products; (2) appropriate best practices, including the then applicable good manufacturing
practices regulations of the International Organization for Standardization (“ISO”) under ISO 9001 certification, ISO 13485 certification and ISO 14001 certification that apply to the manufacture of the Products
(“Applicable Standards”); and (3) other requirements set forth herein. 
 4.2 Regulatory
Approvals. ViewRay will have sole responsibility and authority for obtaining and maintaining regulatory clearance of the ViewRay system incorporating the Product (and all improvements or variations to the Product developed during
the term of this Agreement), including without limitation obtaining and maintaining marketing clearance from the U.S. Food and Drug Administration (“FDA”) under 21 CFR Part 807 or comparable regulations or
comparable regulations of any other supra-national, regional, national, state, or local regulatory agency or authority that has authority to grant registrations, authorizations and approvals necessary for the commercial manufacture, distribution,
marketing, promotion, use, importation, exportation and sale of the ViewRay system incorporating the Product (each, including the FDA, a “Regulatory Authority”). All regulatory filings with the FDA or any other Regulatory
Authority relating to the ViewRay system incorporating the Product will be made in the name of ViewRay or its designee and ViewRay will be responsible for maintaining the Device Master Record for such system. Tesla shall obtain a UL 60601
certification for the Product from Underwriters Laboratories, Inc. and maintain such UL 60601 certification for the Product. 
 4.3
Quality Assurance Inspections. (a) During regular business hours and upon reasonable advance notice and in a manner that does not disrupt or interfere with the business of Tesla, Tesla will permit ViewRay and its agents and its customers to
inspect the facilities of Tesla and provide access to Tesla’s manufacturing quality control documentation related to the Products to the extent necessary for, and for the purpose of assessing Tesla’s compliance with this Agreement. As a
condition of provision to ViewRay agents or ViewRay customers of access to Tesla’s facilities and documentation, all information obtained by ViewRay agents or ViewRay customers as a result of such access will be Tesla Confidential Information
for purposes of this Agreement. Tesla may require any agent or customer of ViewRay seeking access to Tesla’s facilities under this Section 4.3(a), as a condition to such access, to execute a standard confidentiality agreement with Tesla
under which such agent agrees to treat information disclosed during such inspection as the Confidential Information of Tesla under terms and conditions no less restrictive than the terms contained in Section 6.2. 

(b) If an inspection pursuant to Section 4.2(a) reveals that the facilities used to manufacture Products do not satisfy the Applicable
Standards requirements in all material respects, then ViewRay will promptly provide to Tesla written notice of such fact, which notice will contain in reasonable detail the deficiencies found in the manufacturing facilities and, if practicable,
those 
  
 [***] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
steps ViewRay believes Tesla should undertake in order to remedy such deficiencies. Tesla will respond to such notification of deficiencies, remedy such deficiencies within a reasonable period of
time after receipt of such written notice and provide evidence of this corrective action to ViewRay as requested. 
 (c) Tesla will maintain
manufacturing quality documentation and will certify that Product was manufactured and tested in accordance with the applicable Specifications and Applicable Standards and UL 60601 requirements. ViewRay may request copies of such certifications as
part of the inspections permitted under Section 4.3(a). 
 (d) Tesla will comply with Applicable Standards requirements in its
manufacturing of the Products. Prior to shipping any Product, Tesla will carry out the Product tests specified in the applicable Specifications on each Product. If a Product or any part of a Product fails to meet the Specifications, the Product will
be repaired or replaced by Tesla as set forth in Section 7.4.3 and the relevant test will be repeated until such Product passes such test requirements. No Product will be shipped to ViewRay or its designee without passing all tests specified in
the Specifications. Certification of conformance and/or test reports will be provided on request with each unit as evidence of compliance. 
 4.4
Recalls. (a) Prior to the commercial release of the ViewRay system incorporating the Product, ViewRay will provide Tesla with ViewRay’s standard operating procedures (“SOPs”) as to recalls. If either party
becomes aware of information about any Product indicating that it may not conform to the applicable Specifications, it will promptly so notify the other party. The parties will promptly confer to discuss such circumstances and to consider
appropriate courses of action, which courses of action will be consistent with the SOPs. ViewRay will have the right to initiate, and will bear all costs associated with, a recall, withdrawal, or field correction of the Product for any reason;
provided that ViewRay may proceed against Tesla pursuant to Section 7.3 if such recall, withdrawal, or field correction of the Product is the direct result of (i) any breach by Tesla of its duties under the Agreement or
(ii) Tesla’s negligence or willful misconduct. 
 (b) With respect to any recall, withdrawal, or field correction of a Product,
ViewRay or its designee will be responsible for coordinating all of the necessary activities in connection with such recall, withdrawal, or field correction. ViewRay and Tesla will coordinate any statements to customers and the media, including, but
not limited to, press releases and interviews for publication or broadcast and neither party will issue any such statements without consulting with the other and neither party shall identify the other party in any such statements without the other
party’s written consent, not to be unreasonably withheld, except as required by a Regulatory Authority. The parties will reasonably cooperate with each other in the conduct of such activities and will perform any acts reasonably requested by
the other party to facilitate the recall, withdrawal or field correction. Each party will keep the other party fully informed of progress and in relation to all material decisions or actions such party undertakes pursuant to this
Section 4.3(b). 
  
 [***] Certain information in this document has been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c) Each party will promptly (within 2 working days) notify the other party in
writing of any event or complaint that gives rise or could give rise to the need to file a Medical Device Report (an “MDR”) within the meaning of the Federal Food, Drug and Cosmetic Act of 1941, as amended (the
“Act”) or similar report under the laws or regulations administered by any Regulatory Authority (collectively, an “AER”), with respect to any Product or the manufacture, distribution or use thereof in
accordance with the MDR regulation, 21 C.F.R. Part 803 or similar regulations covering AER’s. Each such written notice will be Confidential Information under this Agreement. If, as a result of any corrective action or any final,
non-appealable or non-appealed governmental or court action, an AER is required to be issued for any Product sold hereunder, ViewRay will bear the costs and expenses of and will be responsible for all corrective actions associated with
such AER but may proceed against Tesla pursuant to Section 7.3 if such AER is the direct result of (i) any breach by Tesla of its duties under the Agreement or (ii) Tesla’s negligence or willful misconduct. 

5. LICENSES; PROPRIETARY RIGHTS 
 5.1 Tesla
Licenses. (a) Tesla hereby grants to ViewRay and ViewRay hereby accepts, a worldwide, perpetual, paid-up and royalty-free (except as otherwise set forth in Section 3.10) license, including the
right to grant sublicenses, to use the Tesla Intellectual Property Rights and the Program Intellectual Property Rights owned by Tesla for the purpose of developing Products and delivering services that embody or utilize the Products to customers
within the ViewRay Domain. ViewRay will not use Tesla Intellectual Property for any other purpose, without Tesla’s prior written permission and ViewRay shall not grant, or attempt to grant, a sublicense under this Section 5.1(a) to use
Tesla Intellectual Property Rights, including the Program Intellectual Property Rights owned by Tesla outside the ViewRay Domain without the express written consent of Tesla. 

(b) The license granted under Section 5.1(a) excludes the right to sublicense or otherwise practice the Tesla Intellectual Property and
the Program Intellectual Property owned by Tesla for the purpose of making or having made Products except as otherwise provided under Section 3.10. 

(c) The license granted under this Section 5.1 shall be treated as a license of rights to “intellectual property”
(as defined in Section 101(56) of Title 11 of the United States Code, as amended (the “Bankruptcy Code”)) for purposes of Section 365(n) of the Bankruptcy Code. The parties agree that ViewRay may elect to
retain and may fully exercise all of its rights and elections under the Bankruptcy Code provided, that it abides by the terms of this Agreement. 

(d) It is understood and agreed that the Program commenced on or around March 1, 2009 and that accordingly, the provisions of this
Section 4 with respect to Program Intellectual Property Rights are intended to operate with respect to any Program Intellectual Property conceived, created, discovered, developed, generated, made or reduced to practice or fixed in a tangible
medium of expression as part of or based upon or related to activities undertaken as part of the Program on or after March 1, 2009. 
 5.2 ViewRay
Licenses. ViewRay hereby grants and agrees to grant to Tesla, solely to provide the applicable services under this Agreement and to supply Deliverables (during the Program) and Products (pursuant to Section 3) to ViewRay, a non-exclusive, paid-up and royalty-free license to use the ViewRay Intellectual Property and the Program Intellectual Property owned by 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 
ViewRay in connection with its performance of the Program and its supply of Products pursuant to Section 3. Upon the expiration or termination of the applicable Program work, Tesla’s
license shall terminate and be of no further force or effect. 
 5.3 Reservation of Rights. (a) This Agreement does not convey to ViewRay any
ownership rights in any portion of any Tesla Intellectual Property or the Program Intellectual Property owned by Tesla by implication, estoppel or otherwise, but constitutes only a license to use the Tesla Intellectual Property and the Program
Intellectual Property owned by Tesla as necessary to give effect to the license and in accordance with all of the terms of this Agreement. Title to the Tesla Intellectual Property and the Program Intellectual Property owned by Tesla, shall at all
times remain vested in Tesla. All rights in and to the Tesla Intellectual Property and the Program Intellectual Property owned by Tesla not expressly granted under this Agreement are reserved to and retained by Tesla. 

(b) This Agreement does not convey to Tesla any ownership rights in any portion of the ViewRay Intellectual Property or the Program
Intellectual Property owned by ViewRay by implication, estoppel or otherwise. Title to the ViewRay Intellectual Property and the Program Intellectual Property owned by ViewRay shall at all times remain vested in ViewRay. All rights in and to the
ViewRay Intellectual Property and the Program Intellectual Property owned by ViewRay not expressly granted under this Agreement are reserved to and retained by ViewRay. 

(c) Title to and any interest in Program Intellectual Property described in clause (a) of the Program Intellectual Property definition
shall be the property of Tesla. Title to and any interest in Program Intellectual Property described in clause (b) of the Program Intellectual Property definition shall be the property of ViewRay. Title to and any interest in Program
Intellectual Property described in clause (c) of the Program Intellectual Property definition shall be owned jointly by Tesla and ViewRay; provided, that, except as set forth in subsection (e) below, ViewRay shall not use such
jointly owned Program Intellectual Property except in connection with the practice of the license granted under Section 5.1. 
 (d) For
purposes of this Agreement, except as otherwise set forth in this Agreement, the determination of as to which party invented any invention will be made in accordance with the standards of inventorship and conception under title 35 of U.S. Code
and title 37 of U.S. Code of Federal Regulations. 
 (e) During the term of this Agreement, each party shall promptly disclose to the
other in writing any Program Intellectual Property that might, under applicable law, be patentable or otherwise protectable. Program Intellectual Property (including, without limitation, improvements thereon whether developed by such party or any
employee, or agent of such party) will be added to Attachment 4. Within forty five (45) days following the date of such disclosure regarding the existence of particular Program Intellectual Property (including, without
limitation, improvements thereon whether developed by a party or any employee or agent of such party) that is jointly owned, the parties shall confer and mutually agree as to appropriate protection for such Program Intellectual Property, including
an application, preparation, prosecution and maintenance strategy. If the parties cannot agree upon whether or not to seek patent or other protection with respect to any Program Intellectual Property that is jointly owned, the party 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
desiring to seek such protection may take whatever actions it deems necessary or appropriate to seek such protection in any and all jurisdictions deemed appropriate by such party at its cost and
expense, and the other party shall assign to the party desiring to seek such protection all right, title and interest in and to such Program Intellectual Property and shall cooperate and assist the party seeking such protection in such efforts at
the cost and expense of the party seeking such protection; whereupon the party to which such Program Intellectual Property has been assigned shall grant to the assignor thereof a non-exclusive, worldwide, irrevocable,
paid-up, royalty-free, sublicensable license: (i) if ViewRay is the licensee, to make, have made, use, practice, offer to sell, sell and import, export and otherwise commercially exploit such Program
Intellectual Property within the ViewRay Domain; and (ii) if Tesla is the licensee, to make, have made, use, practice, offer to sell, sell and import, export and otherwise commercially exploit such Program Intellectual Property outside of the
ViewRay Domain. 
 (f) Tesla shall have the sole right, but not the obligation, to file, prosecute, and maintain, at Tesla’s sole
expense, patents covering Program Intellectual Property owned solely by Tesla. Tesla shall promptly furnish or have furnished to ViewRay copies of all patents, patent applications, substantive patent office actions, and substantive responses
received or filed in connection with such applications (excluding patents and patent applications covering solely Tesla Intellectual Property that is not licensed to ViewRay under Section 5.1). In the case of patent applications and responses,
copies will be furnished to ViewRay at least fifteen (15) days before filing or mailing, as the case may be. ViewRay may itself or through its attorney offer comments and suggestions with respect to the matters that are the subject of this
Section 5.3(f) and Tesla agrees to consider such comments and suggestions; provided that nothing herein shall obligate Tesla to adopt or follow such comments or suggestions. ViewRay shall cooperate in the preparation, filing, prosecution
and maintenance of any and all patent applications and patents covering Program Intellectual Property owned solely by Tesla. Tesla shall promptly provide notice to ViewRay as to all matters that come to its attention that may affect the preparation,
filing, prosecution or maintenance of any patents or patent applications covering Program Intellectual Property owned solely by Tesla. In the event that Tesla elects not to file for patent protection or elects not to prosecute or maintain a patent
or patent application in respect of Program Intellectual Property owned solely by Tesla it shall notify ViewRay of such decision at least forty five (45) days prior to the due date of any action or payment due. ViewRay shall then have the
right, but not the obligation, to assume the responsibility therefor at its own cost and expense. It is understood and agreed that a decision by ViewRay to assume responsibility for prosecution or maintenance of a patent or patent application in
respect of Program Intellectual Property owned solely by Tesla shall not result in any change of ownership with respect to such Program Intellectual Property, which shall remain owned by Tesla and subject to the license granted under
Section 5.1. 
 (g) ViewRay shall have the sole right, but not the obligation, to prepare, file, prosecute, and maintain, at
ViewRay’s sole expense, patents covering Program Intellectual Property owned solely by ViewRay. ViewRay shall promptly furnish or have furnished to Tesla copies of all patents, patent applications, substantive patent office actions and
substantive responses relevant to the design or manufacturing practice of gradient coil, resistive or passive shimming structures for use in Magnetic Resonance Imaging received or filed in connection with such applications. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
In the case of such patent applications and responses, copies will be furnished to Tesla at least fifteen (15) days before filing or mailing, as the case may be. Tesla may itself or through
its attorney offer comments and suggestions with respect to the matters that are the subject of this Section 5.3(g) relating to the design or manufacturing practice of gradient coil, resistive or passive shimming structures for use in Magnetic
Resonance Imaging and ViewRay agrees to consider such comments and suggestions; provided that nothing herein shall obligate ViewRay to adopt or follow such comments or suggestions. Tesla shall cooperate in the preparation, filing, prosecution
and maintenance of any and all patent applications and patents covering Program Intellectual Property owned solely by ViewRay. 
 5.4 Enforcement.
(a) Tesla shall be solely responsible for defense and enforcement of Tesla Intellectual Property and Program Intellectual Property owned by Tesla, but in each case subject to the provisions of Section 5.4(b) with respect to enforcement
within the ViewRay Domain. ViewRay shall be solely responsible for the defense and enforcement of ViewRay Intellectual Property and Program Intellectual Property owned by ViewRay. 

(b) Tesla shall have the first option to pursue any enforcement of Tesla Intellectual Property and Program Intellectual Property owned by
Tesla within the ViewRay Domain; provided, that Tesla pays all costs and expenses related to the same, keeps ViewRay reasonably informed of its progress and provides ViewRay with copies of any substantive documents related to such proceedings
and reasonable notice of all such proceedings. Tesla’s costs and expenses in prosecuting or defending such matters shall be subject to reimbursement in accordance with Section 5.4(d). Tesla shall notify ViewRay of its decision to exercise
its right to enforce or defend such intellectual property within the ViewRay Domain not later than ninety (90) days following its discovery or receipt of notice of the alleged infringement. 

(c) If (i) Tesla notifies ViewRay that it will not exercise its option to enforce any intellectual property in accordance with
Section 5.4(b); (ii) ViewRay and Tesla have not otherwise agreed not to pursue or defend against such infringement for business reasons; (iii) Tesla has not persuaded the alleged infringer to desist or the person alleging the
infringement to forebear, (iv) Tesla is not diligently pursuing an infringement action or diligently defending the validity or enforceability of such intellectual property within the ViewRay Domain; or (v) Tesla has not provided ViewRay
with evidence of bona fide negotiations of an acceptable sublicense agreement with the alleged infringer or person alleging infringement, then ViewRay shall have the right to pursue legal action against the alleged infringer or take control of any
action initiated by, or being defended by, Tesla at ViewRay’s own cost and expense. 
 (d) Any recovery of damages in any suit handled
by one party pursuant to Section 5.4(b) or Section 5.4(c) shall be applied first in satisfaction of any unreimbursed expenses and legal fees of the party handling the suit or settlement thereof. The balance of any recovery obtained by
settlement or otherwise shall be distributed: (i) first to [***], and (ii) then to [***] (assuming [***]). The balance, if any, remaining after ViewRay and Tesla have been compensated pursuant to
Section 5.4(d)(i)-(ii) shall be [***]. No settlement, consent judgment or other voluntary final disposition of any suit subject to Section 5.4(b) or Section 5.4(c) may be entered into without
the consent of the other party, which consent shall not be unreasonably withheld. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 (e) In any infringement suit as either party may institute to enforce Intellectual Property
Rights covered by this Section 5.4, or in any declaratory judgment action alleging invalidity or non-infringement of any Intellectual Property Rights covered by this Section 5.4 brought against Tesla or ViewRay, the other party shall, at
the request and expense of the party initiating or defending the suit or action, cooperate and assist in all reasonable respects, having its employees testify when requested and making available relevant records, papers, information, specimens and
the like. 
 6. CONFIDENTIALITY 
 6.1 Publicity.
The terms of this Agreement (including its existence) shall be treated as the Confidential Information of both parties and neither party will issue any press release or make any other statement, written or oral, to the public, the press or
otherwise, relating to this Agreement and the transactions contemplated by this Agreement that has not previously been approved in writing by the other party. Nothing in this Section 6.1 shall prohibit a party from making such disclosures to
the extent required under applicable UK, EU or US federal or state securities laws or any rule or regulation of any nationally recognized securities exchange. In such event, however, the disclosing party shall use good faith efforts to notify and
consult with the other party prior to such disclosure and, where applicable, shall diligently seek confidential treatment to the extent such treatment is available under applicable securities laws. Each party may provide a copy of this Agreement or
disclose the terms of this Agreement: (a) to any finance provider in conjunction with a financing transaction, if such finance provider agrees to keep the terms of this Agreement confidential, (b) to enforce its rights under this Agreement
in a proceeding in accordance with Section 10.2, (c) to any legal or financial advisor of such party, or (d) to current/prospective investors provided such investors are subject to a confidentiality agreement that is consistent with
the terms of Section 6.2 regarding protection of Confidential Information of the other party. 
 6.2 Confidentiality. (a) Confidential
Information of each party will be used by the other party solely for the purposes permitted by this Agreement. All Confidential Information of a disclosing party will be received and held in confidence by the receiving party, subject to the
provisions of this Agreement. Each party acknowledges that, except for the rights expressly granted under this Agreement, it will not obtain any rights of any sort in or to the Confidential Information of the other party as a result of such
disclosure and that any such rights must be the subject of separate written agreement(s). 
 (b) Each party will restrict disclosure of the
other party’s Confidential Information to those of its employees and consultants to whom it is necessary or useful to disclose such Confidential Information in connection with the purposes permitted under this Agreement. Each party shall use
Commercially Reasonable Efforts including at least efforts commensurate with those employed by the party for the protection of its own Confidential Information, to protect the Confidential Information of the other party. 

(c) Nothing herein shall prevent a receiving party from disclosing all or part of the Confidential Information of the other party in response
to a court order or other legal proceeding requesting disclosure of same; provided, the party that receives such order or process provides prompt notice to the disclosing party before making any disclosure (to the extent possible) and 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
permits the disclosing party to oppose or narrow such request for disclosure and supports any of the disclosing party’s reasonable efforts to oppose such request (at disclosing party’s
expense), and only to the extent necessary to comply with such request. Disclosure of Confidential Information pursuant to this Section 6.2(c) will not alter the character of that information as Confidential Information hereunder. 

(d) Either disclosing party may at any time notify the receiving party that such receiving party must return to the disclosing party the
disclosing party’s Confidential Information. Each receiving party hereby agrees to, within thirty (30) days of such notification: (i) return all documents and tangible items it or its employees or agents have received or created
pursuant to this Agreement pertaining, referring or relating to the other party’s Confidential Information; (ii) make all practicable efforts to purge the disclosing party’s Confidential Information from the receiving party’s
computer systems and/or networks without prejudice to the continuing obligations of confidentiality which shall apply to any Confidential Information which for whatever reason may remain on such computer systems or networks; and (iii) return or
certify (in a writing attested to by a duly authorized officer of such party) destruction of all copies, summaries, modifications or adaptations that such party or its employees or agents have made from the materials provided by the disclosing
party; provided, however, that a party is permitted to retain one copy of such materials in its legal files to be used to verify compliance with its obligations hereunder. 

(e) Without prejudice to any other rights or remedies the parties may have under this Agreement, the parties acknowledge for the benefit of
one another that damages may not be an adequate remedy for any breach of Section 6 and that, accordingly, a party shall be entitled without proof of special damage to the remedies of injunction and specific performance and other equitable
remedies for any threatened or actual breach of Section 6 by the other party. 
 7. REPRESENTATIONS AND WARRANTIES. 

7.1 Authorization; Enforceability. Each of ViewRay and Tesla represents and warrants to the other party that: (a) it is duly organized and validly
existing under the laws of its jurisdiction of organization and has all requisite power and authority to enter into this Agreement; (b) it is duly authorized by all requisite action to execute, deliver and perform this Agreement and to
consummate the transactions contemplated hereby, and that the same do not conflict or cause a default with respect to such party’s obligations under any other agreement; (c) it has duly executed and delivered this Agreement; and
(d) it is authorized to disclose any and all Confidential Information made available to the other party pursuant to this Agreement. 
 7.2
Products. (a) Tesla warrants to ViewRay that all Products supplied to ViewRay pursuant to Section 3 shall: (i) for a period of twelve (12) months from the date of acceptance by the ViewRay customer but not more than eighteen
(18) months from the date of shipment to ViewRay, whichever is longer, conform to its then current published specifications and documentation and the Specifications (provided that in the event of a conflict between the Specifications and the
published specifications or documentation, the terms of the Specifications will control), and (ii) be manufactured, labeled, packaged, stored and tested (while in the possession or control of Tesla) in accordance with the Specifications and the
applicable laws and regulations in relation to the manufacture and testing of the Product (including all Applicable Standards). This warranty does not apply to any non-conformity of the Products resulting from misuse, mishandling or storage
in an improper environment in each case by any party other than Tesla or its agents. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 (b) Tesla warrants to ViewRay that all Products shall be delivered free and clear of all liens
and encumbrances. 
 7.3 Remedy. In the event any Products purchased by ViewRay from Tesla fail to conform to the warranty set forth in
Section 7.2, Tesla shall, at Tesla’s option, repair or replace the Products. ViewRay shall notify Tesla of any such nonconformity and return the applicable Products in accordance with Section 3.9. It is understood and agreed that the
remedy set forth in this Section 7.3 shall not limit either party’s other remedies at law or equity, including a party’s remedies with respect to third party claims arising pursuant to
Sections 8.2-8.3. 
 7.4 Disclaimer. (a) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS 7.1-7.2, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF
FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY MATTER WHATSOEVER, INCLUDING BUT NOT LIMITED TO, THE PRODUCTS. 
 (b) THE
REPRESENTATIONS AND WARRANTIES OF EACH OF TESLA AND VIEWRAY EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED IN SECTIONS 8.2-8.3. 
 8. RISK ALLOCATION 

8.1 Limitation of Liability. (a) EXCEPT FOR BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER SECTION 6 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS 8.2-8.3 WITH RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR
EXEMPLARY DAMAGES IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, REGARDLESS OF WHETHER THE PARTIES HAVE ADVISED OR BEEN ADVISED OF THE POSSIBILITY OF ANY SUCH LOSS
OR DAMAGE. 
 (b) IN ADDITION TO THE LIMITATION OF LIABILITY SET FORTH IN SECTION 8.1(a), IT IS UNDERSTOOD AND AGREED THAT IN NO EVENT
SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR AGGREGATE DAMAGES ARISING UNDER OR IN CONNECTION WITH THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, AND [***] AND [***] IN EXCESS OF [***] IN THE AGGREGATE. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c) NOTHING IN THIS AGREEMENT, INCLUDING
SECTIONS 8.1(a)-(b), SHALL LIMIT OR EXCLUDE THE LIABILITY OF EITHER PARTY FOR (I) THIRD PARTY CLAIMS FOR DEATH OR PERSONAL INJURY RESULTING FROM SUCH PARTY’S NEGLIGENCE; (II) CLAIMS BASED
ON BREACH OF ANY TERMS IMPLIED IN RESPECT OF TESLA’S ABILITY TO PASS TITLE TO THE PRODUCTS; OR (III) CLAIMS BASED ON FRAUD OR FRAUDULENT MISREPRESENTATION. 

8.2 Indemnification of ViewRay. Subject to the provisions of Section 8.4, Tesla will defend, indemnify, and hold harmless ViewRay and its
Affiliates, officers, directors, employees, agents, and their successors and assigns (each, in such capacity, an “ViewRay Indemnified Party”) from and against any claim, suit, demand, loss, damage, expense (including
reasonable attorneys’ fees of ViewRay Indemnified Party(ies) and those that may be asserted by a third party) or liability (collectively, “Losses”) arising from any third party claim or proceeding against the ViewRay
Indemnified Party(ies) by any third party to the extent that such claim or proceeding is based on: (a) a third party assertion that the Products infringe any third party Intellectual Property Rights; or (b) a third party allegation of
product liability or personal injury arising from or relating to a failure of the Products. The foregoing indemnification action shall not apply in the event and to the extent that such Losses arose as a result of any ViewRay Indemnified
Party’s negligence, intentional misconduct or breach of this Agreement. 
 8.3 Indemnification of Tesla. Subject to the provisions of
Section 8.4, ViewRay will defend, indemnify, and hold harmless Tesla and its Affiliates, officers, directors, employees, agents, and their successors and assigns (each, in such capacity, an “Tesla Indemnified Party”)
from and against any Losses arising from any third party claim or proceeding against the Tesla Indemnified Party(ies) by any third party to the extent that such claim or proceeding is based on: (a) any third party allegation of infringement of
third party Intellectual Property Rights, where such claim is based upon the combination, operation or use of the Products with non-Tesla technology and products in a manner not explicitly contemplated by this Agreement, if such claim of
infringement would have been avoided but for such combination, operation or use; or (b) any third party allegation of product liability or personal injury arising from or relating to the ViewRay products or services (other than due to the
failure of a Product). The foregoing indemnification action shall not apply in the event and to the extent that such Losses arose as a result of any Tesla Indemnified Party’s negligence, intentional misconduct or breach of this Agreement. 

8.4 Procedure. To receive the benefit of indemnification under Section 8.2 or Section 8.3, the ViewRay Indemnified Party or Tesla Indemnified
Party, as applicable, must: (a) promptly notify the party from whom indemnification is sought (each, an “Indemnifying Party”) of any claim or proceeding; provided, that failure to give such notice shall not
relieve Indemnifying Party of its indemnification obligations except where, and solely to the extent that, such failure actually and materially prejudices the rights of Indemnifying Party; (b) provide reasonable cooperation to the Indemnifying
Party (and its insurer), as reasonably requested, at Indemnifying Party’s cost and expense; and (c) tender to the Indemnifying Party (and its insurer) full authority to defend or settle the claim or suit; provided that no settlement
requiring any admission by the Indemnified Party or that imposes any obligation on the Indemnified Party shall be made without the 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 
Indemnified Party’s consent. Neither party has any obligation to indemnify the other party in connection with any settlement made without the Indemnifying Party’s written consent. The
Indemnified Party has the right to participate at its own expense in the claim or suit and in selecting counsel therefor. 
 8.5 Insurance.
Each party shall procure and maintain insurance, including product liability insurance, adequate to cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated. It is understood
that such insurance shall not be construed to create a limit of either party’s liability with respect to its indemnification obligations under this Section 8. Each party shall cause the other to be listed as an additional named insured on
such policy(ies) and shall provide the other with written evidence of such insurance upon request. Each party shall provide the other with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in
such insurance or self-insurance which materially adversely affects the rights of the other party hereunder. If such party does not obtain replacement insurance or take other measures that allow it to provide comparable coverage within such 15-day period, the other party shall have the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 

9. TERM AND TERMINATION 
 9.1 Term. This Agreement
shall take effect as of the Effective Date and shall remain in effect until the fifth anniversary of the Effective Date (the “Term”), unless sooner terminated in accordance with Section 2.5 or Section 9.2.
Thereafter, this Agreement will renew automatically for additional one-year terms unless either party provides the other party with written notice at least twelve (12) months in advance of the scheduled renewal date. 

9.2 Termination. (a) During the term of the Program, either party may terminate the Program and this Agreement upon thirty (30) days written
notice to the other party if the other party commits a material breach of this Agreement, unless such breach is cured within the thirty (30) day notice period, or if such breach is not capable of being cured within thirty (30) days unless
such party during such thirty (30) day period initiates actions reasonably expected to cure the breach and thereafter diligently proceeds to cure the breach. Except for termination by Tesla based upon non-payment by ViewRay of amounts due under
this Agreement, termination of the Program pursuant to this Section 9.2(a) shall not result in termination of this Agreement except as otherwise provided in Section 9.2(c). The parties may also terminate the Program at any time in
accordance with the procedure specified in Section 2.5. 
 (b) Following completion of the Program and, with respect to matters not
directly related to the Program at any time during or following completion of the Program, either party may terminate this Agreement upon sixty (60) days written notice to the other party if the other party commits a material breach of this
Agreement (other than non-payment), unless such breach is cured within the sixty (60) day notice period, or if such breach is not capable of being cured within sixty (60) days unless such party during such sixty (60) day period
initiates actions reasonably expected to cure the breach and thereafter diligently proceeds to cure the breach. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 (c) The parties may parties may terminate this Agreement at any time by mutual agreement. ViewRay
may also terminate this Agreement in accordance with Section 3.11(a). 
 (d) The disadvantaged party (as defined in Section 10.14)
shall have the right to terminate this Agreement upon thirty (30) days notice if a Force Majeure condition has prevented performance by the other party for more than sixty (60) consecutive days or an aggregate one hundred twenty
(120) days in any 12-month period. 
 9.3 Effect of Termination. (a) Upon termination of the
Program pursuant to Section 9.2(a): (i) Tesla will terminate all Program tasks then in process in an orderly manner, as soon as practical and in accordance with a schedule agreed to by ViewRay and Tesla; (ii) Tesla shall deliver to
ViewRay a reasonably-detailed written report describing the results of the Program up to the date of such termination; and (iii) ViewRay shall pay Tesla any monies due and owing Tesla as of the time of termination for work that has been
completed. 
 (b) Upon any termination (including expiration) of this Agreement each party shall return to the other party or certify in
writing to the other party that it has destroyed all documents (including those stored on computer systems and networks) and other tangible items it or its employees or agents have received or created pertaining, referring or relating to the
Confidential Information of the other party; provided, that a party is permitted to retain one copy of such materials in its legal files to be used to verify compliance with its obligations hereunder. 

(c) Upon termination or expiration of this Agreement for any reason ViewRay will have the right to continue to sell all unsold Products that
are in its possession or that are subject to an open ViewRay Purchase Order as of the effective date of such termination or expiration. In addition, Tesla will continue to supply ViewRay with Products for a period of [***] after expiration or
termination of this Agreement for any reason to wind-down the supply of Products for ViewRay from Tesla, provided that if termination was effected by Tesla as a result of ViewRay’s material breach of this Agreement then ViewRay will
promptly pay all sums due Tesla under this Agreement as of the date of termination. The supply of Products by Tesla pursuant to this Section 9.3(c) shall be subject to the provisions of 4-9 excluding
[***]. 
 (d) Upon termination or expiration of this Agreement for any reason ViewRay will pay Tesla ([***]) an [***] to the extent that
(i) [***]; (ii) [***] or for itself; and (iii) at ViewRay’s request and transportation cost, Tesla delivers such materials to ViewRay; provided, that ViewRay’s obligations under this Section 9.3(d) shall not
exceed in the aggregate [***] of the [***] for the [***]. 
 (e) Nothing herein shall be construed to release either party of any obligation
which matured prior to the effective date of any termination. Either party’s liability for any uncontested charges, payments or expenses due to the other party that accrued prior to the termination date shall not be extinguished by termination,
and such amounts (if not otherwise due on an earlier date) shall be immediately due and payable on the termination date. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 9.4 Survival. Sections 1, 2.1, 5-8, 9.3 (and the
Sections of this Agreement referenced therein), 9.4 and 10 shall survive any termination or expiration of this Agreement. Section 2.2 shall survive any termination or expiration of this Agreement; provided that Section 2.2 shall not
survive termination of this Agreement by ViewRay pursuant to Section 9.1 or termination of the Program by the parties pursuant to Section 9.2(b). 

10. GENERAL PROVISIONS. 
 10.1 Governing
Law. This Agreement shall be governed and construed in accordance with the internal, substantive laws of Delaware, to the exclusion of any choice or conflict of laws rule or provision that would result in the application of the
substantive law of any other jurisdiction. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement or the transactions contemplated by this Agreement. 

10.2 Dispute Resolution. (a) The parties will attempt to settle any claim or controversy arising out of this Agreement or the subject
matter hereof through consultation and negotiation in good faith in a spirit of mutual cooperation. Such matters will be initially addressed by the Director of MRI Engineering of ViewRay and the Engineering Director of Tesla, who shall use
reasonable efforts to attempt to resolve the dispute through good faith negotiations by telephone or in person as may be agreed. If they fail to resolve the dispute within thirty (30) days after either party notifies the other of the dispute,
then the matter will be escalated to the Sr. VP of Engineering of ViewRay and the Operations Director of Tesla, or their designees for resolution. They will use reasonable efforts to attempt to resolve the dispute through good faith negotiations by
telephone or in person as may be agreed. If they fail to resolve the dispute within thirty (30) days after it is referred to them and do not mutually agree to extend the time for negotiation, then the dispute will be submitted to arbitration in
accordance with the procedure set forth in Section 10.2(b). 
 (b) Except with respect to actions by either party seeking equitable or
declaratory relief, any claim or controversy arising in whole or in part under or in connection with this Agreement or the subject matter hereof that is not resolved pursuant to Section 10.2(a) will be referred to and finally resolved by
arbitration in accordance with the Commercial Arbitration Rules (the “Rules”) of the American Arbitration Association as such Rules may be modified by this Agreement, by one arbitrator, who will be agreed upon by the parties.
If the parties are unable to agree upon a single arbitrator within thirty (30) days following the date arbitration is demanded, three arbitrators will be used, one selected by each party within ten (10) days after the conclusion of the 30-day period and a third selected by the first two within 10 days thereafter. Unless the parties agree otherwise, they will be limited in their discovery to directly relevant documents. Responses or objections
to a document request will be served twenty (20) days after receipt of the request. The arbitrator(s) will resolve any discovery disputes. The foregoing arbitration proceedings may be commenced by either party by notice to the other party.
Unless otherwise agreed by the parties, all such arbitration proceedings will be held in New York, New York if initiated by Tesla and in London, England if initiated by ViewRay; provided that proceedings may be conducted by telephone
conference call with the consent of the arbitrator. All arbitration proceedings will be conducted in the English language and the arbitrator(s) will apply the law of Delaware. The arbitrator(s) will only have the authority to award actual money
damages (with interest on unpaid amounts from the date due) and, except with respect to a breach or nonperformance of any provision of this Agreement relating to Confidential Information, the 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
arbitrator(s) will not have the authority to award indirect, incidental, consequential, exemplary, special or punitive damages, and the parties expressly waive any claimed right to such damages.
The arbitration will be of each party’s individual claims only, and no claim of any other party will be subject to arbitration in such proceeding. The costs and expenses of the arbitration, but not the costs and expenses of the parties, will be
shared equally by the parties. If a party fails to proceed with arbitration, unsuccessfully challenges the arbitration award, or fails to comply with the arbitration award, the other party is entitled to costs, including reasonable attorneys’
fees, for having to compel arbitration or defend or enforce the award. Except as otherwise required by law, the parties and the arbitrator(s) will maintain as confidential all information or documents obtained during the arbitration process,
including the resolution of the dispute. Judgment on the award granted in any arbitration hereunder may be entered in any court having jurisdiction over the award or any of the parties or any of their respective assets. The provisions of this
Section 10.2(b) will not apply to any claim or controversy involving infringement or misappropriation of any Intellectual Property Right of either party, in which case the Claim or controversy may be brought in the state or federal court
located in the Southern District of New York. The parties knowingly and voluntarily waive their rights to have their dispute tried and adjudicated by a judge and jury except as expressly provided herein. 

10.3 Amendment and Waiver. No provision of or right under this Agreement shall be deemed to have been waived by any act or acquiescence on the
part of either party, its agents or employees, but only by an instrument in writing signed by an authorized officer of each party. No waiver by either party of any breach of this Agreement by the other party shall be effective as to any other
breach, whether of the same or any other term or condition and whether occurring before or after the date of such waiver. 
 10.4 Independent
Contractors. Each party represents that it is acting on its own behalf as an independent contractor and is not acting as an agent for or on behalf of any third party. This Agreement and the relations hereby established by and between
ViewRay and Tesla do not constitute a partnership, joint venture, franchise, agency or contract of employment. Neither party is granted, and neither party shall exercise, the right or authority to assume or create any obligation or responsibility on
behalf of or in the name of the other party or its Affiliates. Each party shall be solely responsible for compensating all its personnel and for payment of all related FICA, workers’ compensation, unemployment and withholding taxes. Neither
party shall provide the other party’s personnel with any benefits, including but not limited to compensation for insurance premiums, paid sick leave or retirement benefits. 

10.5 Assignment. Neither party may assign this Agreement or any of its rights and obligations under this Agreement without the prior written
consent of the other party; provided, that either party may assign this Agreement without the consent of the other party to an Affiliate or in connection with any merger, acquisition, or sale a majority of such party’s voting stock or a
sale of substantially all such party’s assets; provided, further, that in each instance the assignee expressly assumes all obligations imposed on the assigning party by this Agreement in writing and the other party is notified in
advance of such assignment. Any purported assignment in violation of this Section 10.5 shall be null and void. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 10.6 Successors and Assigns. This Agreement shall bind and inure to the benefit of the parties hereto and
their respective successors and permitted assigns. 
 10.7 Notices. Unless otherwise provided herein, any notice, report, payment or document
to be given by one party to the other shall be in writing and shall be deemed given when delivered personally or mailed by certified or registered mail, postage prepaid (such mailed notice to be effective on the date which is three (3) Business
Days after the date of mailing), or sent by nationally recognized overnight courier (such notice sent by courier to be effective one (1) Business Day after it is deposited with such courier), or sent by telefax (such notice sent by telefax to
be effective when sent, if confirmed by certified or registered mail or overnight courier as aforesaid) to the address set forth on the signature page to this Agreement or to such other place as any party may designate as to itself by written notice
to the other party. 
 10.8 Severability. In the event any provision of this Agreement shall for any reason be held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof. The parties agree that they will negotiate in good faith or will permit a court to replace any provision hereof so
held invalid, illegal or unenforceable with a valid provision which is as similar as possible in substance to the invalid, illegal or unenforceable provision. 

10.9 Captions. Captions of the sections and subsections of this Agreement are for reference purposes only and do not constitute terms or
conditions of this Agreement and shall not limit or affect the meaning or construction of the terms and conditions hereof. 
 10.10 Word
Meanings. Words such as herein, hereinafter, hereof and hereunder refer to this Agreement as a whole and not merely to a section or paragraph in which such words appear, unless the context otherwise requires. The singular shall include
the plural, and each masculine, feminine and neuter reference shall include and refer also to the others, unless the context otherwise requires. 
 10.11
Entire Agreement. The terms and provisions contained in this Agreement (including the Attachments) constitute the entire understanding of the parties with respect to the transactions and matters contemplated hereby and supersede all
previous communications, representations, agreements and understandings relating to the subject matter hereof. No representations, inducements, promises or agreements, whether oral or otherwise, between the parties not contained in this Agreement
shall be of any force or effect. No agreement or understanding extending this Agreement or varying its terms (including any inconsistent terms in any purchase order, acknowledgment or similar form) shall be binding upon either party unless it is in
a writing specifically referring to this Agreement and signed by a duly authorized representative of the applicable party. 
 10.12 Rules of
Construction. The parties agree that they have participated equally in the formation of this Agreement and that the language and terms of this Agreement shall not be construed against either party by reason of the extent to which such
party or its professional advisors participated in the preparation of this Agreement. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 10.13 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be accepted as original signatures, orders may be transmitted electronically and any document created pursuant to this Agreement
may be maintained in an electronic document storage and retrieval system, a copy of which shall be considered an original. 
 10.14 Force
Majeure. Except as otherwise provided in this Agreement, in the event that a delay or failure of a party to comply with any obligation created by this Agreement is caused by wars (declared or undeclared and including the continuance,
expansion or new outbreak of any war or conflict now in existence), revolution, civil commotion, acts of public enemy, labor strikes (other than employees of the affected party), terrorism, embargo or acts of government in its sovereign capacity,
any change in the law or interpretation of the law that renders performance in accordance with the terms of this Agreement illegal, fire, explosion or accidental damage, loss at sea, adverse weather conditions, collapse of building structures,
interruption or failure of utility service (including but not limited to electric power, gas or water) (“Force Majeure”), the “affected party” will, after giving prompt notice to the “disadvantaged party,” be excused
from such performance on a day-to-day basis during the continuance of such prevention, restriction, or interference (and the disadvantaged party will likewise be excused from performance of its obligations on a day-to-day basis during the same
period), provided, however, that the affected party will use its best efforts to avoid or remove the causes of nonperformance and both parties will proceed immediately with the performance of their obligations under this Agreement whenever the
causes are removed or cease. If Force Majeure conditions continue for more than 60 consecutive days or an aggregate 120 days in any 12-month period, then the disadvantaged party may terminate this
Agreement in accordance with Section 9.2(d). 
 10.15 Non-Solicitation. Neither Tesla nor ViewRay shall (except with the prior written
consent of the other) at any time during the term of this Agreement and for a further period of 12 months following termination of this Agreement directly or indirectly solicit or entice away (or attempt to solicit or entice away) from the
employment of the other any person employed by such other. If either party commits any breach of the obligations in the preceding sentence, and without prejudice to all and any other legal or equitable remedies available to the other party which are
expressly reserved, the breaching party shall, on demand, pay to the other party a sum equal to one year’s basic salary or the annual fee that was payable by the other party to that employee. Tesla and ViewRay agree that the mutual
non-solicitation obligation set out in this Section 10.15 shall not apply to either party if a person is recruited following national advertising campaigns in both the UK and US provided that such campaigns are open to all comers and not
specifically targeted at any of the staff of the other party, and that any initial approach after such advertising campaign is made unsolicited by the employee himself or herself to the party advertising. 

[remainder of this page intentionally left blank] 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 10.16 Further Assurances. Each party covenants and agrees that, subsequent to the execution and
delivery of this Agreement and without any additional consideration, it will execute and deliver any further legal instruments and perform any acts which are or may become reasonably necessary to effectuate the purposes of this Agreement. 

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on their behalf by their duly authorized representatives intending it to take effect
as an instrument under seal as of the Effective Date. 
  

									
	TESLA ENGINEERING LIMITED	 		 	VIEWRAY INCORPORATED
					
	By:	 	/s/ Stephen Bates	 		 	By:	 	/s/ Greg Ayers
		 		 		 	Greg Ayers, Acting Chief Executive Officer
			
	 Notice Address:
 Tesla
Engineering Limited
 Water Lane
 Storington, West Sussex R1120
3EA
 United Kingdom
 Phone: [***]

Fax: [***]
	 		 	 Notice Address:
 ViewRay
Incorporated
 #2 Thermo Fisher Way
 Oakwood Village, OH
44146
 United States
 Phone: [***]

Fax: [***]

  

			
	Attachment 1	  	Specifications; Program
	Attachment 2	  	Pricing
	Attachment 3	  	Escrow Agreement
	Attachment 4	  	Program Intellectual Property
	Attachment 4a	  	Tesla Intellectual Property
	Attachment 4b	  	ViewRay Intellectual Property
	Attachment 5	  	Quality

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Attachment 1 

Program; Specifications 

Tesla Services: 
 ViewRay requires
the development of a Product as specified in ViewRay Requirements attached below which provides the detailed Specifications for each of the Deliverables. The development is [***]: 

 

									
	 Phase
	  	Scope and Activities	 	 	Deliverables	 
	 [***]
	  	 	[	***] 	 	 	[	***] 

 Schedule: 
 It is
understood that an accelerated schedule is of great importance to ViewRay. With this in mind, the following schedule is planned. 
 [***]

 ViewRay shall pay a bonus to Tesla as per Attachment 2 if the prototype coil is completed and ready for shipment by
[***]. 
 Pricing: See Attachment 2. 

ViewRay’s responsibilities: 
 The following
shall be ViewRay’s responsibilities. 
 [***] 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 SPECIFICATIONS: 

[***] 
 [***] Seven pages in this document have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Attachment 2 

Pricing 
 The amount to be paid for
each accepted Deliverable under Section 2.3 shall be as follows: 
  

	1.	Tesla’s fees will be calculated on a [***]. The [***]; and during the initial year of this Agreement the [***]. Upon the commencement of each Phase of the Program set forth in
Attachment 1, ViewRay will pay Tesla an amount equal to [***] of the Nominal Amount allocated to that Phase under Table 2 (below) as an advance against the price due in respect of the services and Deliverables for such
Phase. 

  

	2.	Upon ViewRay’s Acceptance of the final Deliverable specified in Attachment 1 for each Phase of the Program, Tesla shall bill ViewRay for an amount equal to the (A) [***] as of the
date of the Acceptance of the final Deliverable for such Phase [***], minus (B) the advance previously paid Tesla for such Phase. 

  

	3.	Notwithstanding any provision of this Agreement to the contrary, the maximum price that may be charged for any Phase is the Not To Exceed Amount set forth in Table 2 and Tesla shall be responsible to deliver all the
Deliverables for each Phase at a price that does not exceed the Not to Exceed Amount. 

  

	4.	In the event that Tesla aggregate fees for a Phase of the Program at the time of ViewRay’s Acceptance of the final Deliverable specified in Table 1 for such Phase are less than the Nominal Amount for such
Phase specified in Table 2, ViewRay will [***] as of the time of ViewRay’s Acceptance of the final Deliverable for such Phase. 

  

	5.	Payment of invoices shall be as specified in Section 3.1 of the Agreement. 

  

	6.	Tesla will keep and maintain complete and accurate records of the time and work performed under this Statement of Work. Tesla will provide with each invoice delivered pursuant to Paragraph 2, a detailed time record
organized in one (1) hour increments. Such records will be open to inspection and review by ViewRay upon ViewRay’s prior written request to Tesla during the term of this Statement of Work and for a period of [***] following the expiration
or termination of this Statement of Work. 

  

							
	 Table 2

	 Phase
	  	Nominal Material and
Labor Costs	 	Nominal Amount	 	Not to Exceed Amount
	 [***]
	  	[***]	 	[***]	 	[***]

  

	7.	The pricing specified above excludes the following items: none. 

  

	8.	The pricing for Products in [***] shall be as set forth in Section 3.5 subject to the following volume discounts: 

  

					
	 Units Purchased (per year)
	  	Price per unit	 
	 1-TBD
	  	$	TBD	  
	 TBD
	  	 	TBD	  
	 TBD
	  	 	TBD	  

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 The volume discounts of this section are contingent upon the “agreed pricing” model and will be
determined as part of the “agreed pricing” negotiation. In the case that the [***]. 
  

	9.	ViewRay shall pay an early completion bonus of $[***] plus ViewRay will pay to Tesla the difference between the [***] above if the first prototype gradient coil of Phase 2 is completed, delivered to ViewRay and
meets Acceptance Testing by [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Attachment 3 

Escrow Agreement 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 Attachment 4a 

Tesla’s IP & Patents 

Know How 
 [***] 

PATENT LIST 

[***] 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 Attachment 4b 

[***] 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 Attachment 5 

Quality 
 [***] 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]